"test_results=[TestResult(name='test_case_2', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.18115857775414584, reason=\"The actual output does not mention the SIOP\u22122001 protocol's success, despite listing relevant protocols.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028336499999999996, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=0.9565217391304348, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.007014149999999999, verbose_logs='Truths (limit=None):\\n[\\n    \"The document is titled \\'sample.pdf\\'.\",\\n    \"The authors of the document include Marry M. van den Heuvel-Eibrink, Janna A. Hol, Kathy Pritchard-Jones, Harm van Tinteren, Rhoikos Furtw\u00e4ngler, Arnauld C. Verschuur, Gordan M. Vujanic, Ivo Leuschner, Jesper Brok, Christian R\u00fcbe, Anne M. Smets, Geert O. Janssens, Jan Godzinski, Gema L. Ram\u00edrez-Villar, Beatriz de Camargo, Heidi Segers, Paola Collini, Manfred Gessler, Christophe Bergeron, Filippo Spreafico, and Norbert Graf.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group and SIOP\u2013RTSG are organizations mentioned in the document.\",\\n    \"The document discusses Wilms tumour, a type of cancer.\",\\n    \"The document mentions various treatment protocols, including the UMBRELLA SIOP\u2013RTSG 2016 protocol and SIOP\u20132001 protocol.\",\\n    \"The document references childhood renal tumours, which include Wilms tumours.\",\\n    \"The document mentions the drug doxorubicin as part of the treatment for childhood renal tumours.\",\\n    \"It includes treatment options such as actinomycin D and vincristine in combination with other therapies.\",\\n    \"Childhood renal tumours can be associated with genomic changes, specifically 1q.\",\\n    \"The website www.siop-rtsg.eu is associated with the document.\",\\n    \"The document includes references to clinical trials such as the SIOP\u22122001 randomized trial and the UKW3 trial.\",\\n    \"The document addresses high-risk, blastemal-type Wilms tumours as a subtype of Wilms tumour.\",\\n    \"The document mentions various organizations involved in research and treatment of renal tumours, including the Children\u2019s Oncology Group (COG) and UK Children\u2019s Cancer and Leukaemia Group (UKCCLG).\",\\n    \"It includes specific risk categories for Wilms tumour, which are low-risk, intermediate-risk, and high-risk disease categories.\",\\n    \"The document references survival metrics such as event-free survival (EFS) and overall survival (OS).\",\\n    \"The document discusses diagnostic and treatment fields relevant to paediatric oncology.\",\\n    \"Surgery, chemotherapy, and radiotherapy are discussed as treatment options for Wilms tumour.\",\\n    \"The document details various medical conditions related to Wilms tumours, including metastatic disease and pulmonary nodules.\",\\n    \"It contains information regarding research studies, treatments, and protocols used in the management of Wilms tumours in children and adults.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author of the document sample.pdf.\",\\n    \"Janna A. Hol is an author of the document sample.pdf.\",\\n    \"Kathy Pritchard-Jones is an author of the document sample.pdf.\",\\n    \"Harm van Tinteren is an author of the document sample.pdf.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author of the document sample.pdf.\",\\n    \"Arnauld C. Verschuur is an author of the document sample.pdf.\",\\n    \"Gordan M. Vujanic is an author of the document sample.pdf.\",\\n    \"Ivo Leuschner is an author of the document sample.pdf.\",\\n    \"Jesper Brok is an author of the document sample.pdf.\",\\n    \"Christian R\u00fcbe is an author of the document sample.pdf.\",\\n    \"Anne M. Smets is an author of the document sample.pdf.\",\\n    \"Geert O. Janssens is an author of the document sample.pdf.\",\\n    \"Jan Godzinski is an author of the document sample.pdf.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author of the document sample.pdf.\",\\n    \"Beatriz de Camargo is an author of the document sample.pdf.\",\\n    \"Heidi Segers is an author of the document sample.pdf.\",\\n    \"Paola Collini is an author of the document sample.pdf.\",\\n    \"Manfred Gessler is an author of the document sample.pdf.\",\\n    \"Christophe Bergeron is an author of the document sample.pdf.\",\\n    \"Filippo Spreafico is an author of the document sample.pdf.\",\\n    \"Norbert Graf is an author of the document sample.pdf.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization that contributed to the document sample.pdf.\",\\n    \"SIOP\u2013RTSG is an organization that contributed to the document sample.pdf.\",\\n    \"Wilms tumour is a medical condition mentioned in the document sample.pdf.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol described in the document sample.pdf.\",\\n    \"Childhood renal tumours is a medical condition mentioned in the document sample.pdf.\",\\n    \"The SIOP\u20132001 protocol is a protocol described in the document sample.pdf.\",\\n    \"The genomic change 1q is mentioned in the document sample.pdf.\",\\n    \"The website www.siop-rtsg.eu is referenced in the document sample.pdf.\",\\n    \"The renal tumour patients are a group mentioned in the document sample.pdf.\",\\n    \"The Consensus Statement is a document referred to in the sample.pdf.\",\\n    \"Wilms tumours is a medical condition mentioned in the document sample.pdf.\",\\n    \"The UMBRELLA protocol is referred to in the document sample.pdf.\",\\n    \"Diagnostics is a field mentioned in the document sample.pdf.\",\\n    \"Treatment is a field mentioned in the document sample.pdf.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization mentioned in the document sample.pdf.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial referred to in the document sample.pdf.\",\\n    \"Doxorubicin is a drug mentioned in the document sample.pdf.\",\\n    \"Actinomycin D is a drug mentioned in the document sample.pdf.\",\\n    \"Vincristine is a drug mentioned in the document sample.pdf.\",\\n    \"The UKW3 trial is a clinical trial referred to in the document sample.pdf.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization mentioned in the document sample.pdf.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document sample.pdf.\",\\n    \"Vincristine is a chemical mentioned in the document sample.pdf.\",\\n    \"Actinomycin D is a chemical mentioned in the document sample.pdf.\",\\n    \"Doxorubicin is a chemical mentioned in the document sample.pdf.\",\\n    \"Event-free survival (EFS) is a medical metric mentioned in the document sample.pdf.\",\\n    \"Overall survival is a medical metric mentioned in the document sample.pdf.\",\\n    \"The SIOP-2001 is a clinical trial description included in the document sample.pdf.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim about the Consensus Statement is incorrect as the retrieval context does not provide any information on this document.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.4, reason=\"The score is 0.40 because the relevant statements, such as 'The UMBRELLA SIOP\u2013RTSG 2016 protocol aims to improve treatment for patients with Wilms tumours,' do not clearly specify what the protocol aims to replace, which is the key focus of the input.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0032960999999999997, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol aims to improve treatment for patients with Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumours are a common pediatric kidney cancer.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement does not relate to the specific aim of the protocol, which is to replace existing treatment methods. It mentions \\'a common pediatric kidney cancer\\' but does not specify what it specifically aims to replace.\"\\n            },\\n            {\\n                \"statement\": \"This protocol is an evolution of the previous SIOP\\\\u20132001 protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The organization involved is the International Society of Paediatric Oncology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The mention of the organization does not directly answer the question about the protocol\\'s aim to replace something.\"\\n            },\\n            {\\n                \"statement\": \"Childhood renal tumours can be diverse in pathology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This does not address what the protocol aims to replace, instead it discusses the pathology of renal tumours.\"\\n            },\\n            {\\n                \"statement\": \"The protocol defines treatment strategies for high-risk, blastemal-type Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Chemotherapy agents like doxorubicin and vincristine are often used.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement discusses chemotherapy agents but does not provide information on what the protocol aims to replace.\"\\n            },\\n            {\\n                \"statement\": \"There are various guidelines set by SIOP for treatment of these tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While it mentions guidelines, it does not specify the aim of replacing any specific treatment protocol.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG protocol incorporates new findings in treating Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Children with Wilms tumours will benefit from multi-institutional studies.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement lacks information on what specific aspect the protocol aims to replace in treatment.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What does the protocol aim to replace?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='It succeeds the SIOP\u22122001 protocol.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_5', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=True, score=1.0, reason=\"The actual output correctly includes 'chest CT' detecting 'pulmonary nodules', matching the expected output.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028342499999999995, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0070183500000000005, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author associated with the document \\'sample.pdf\\'.\",\\n    \"The \\'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group\\' is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"The \\'SIOP\u2013RTSG\\' is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'UMBRELLA SIOP\u2013RTSG 2016 protocol\\' is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'SIOP\u20132001 protocol\\' is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The genomic change \\'1q\\' is referenced in the document \\'sample.pdf\\'.\",\\n    \"The website \\'www.siop-rtsg.eu\\' is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients are referenced in the document \\'sample.pdf\\'.\",\\n    \"The document \\'Consensus Statement\\' is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumours are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'UMBRELLA protocol\\' is referenced in the document \\'sample.pdf\\'.\",\\n    \"Diagnostics and treatment fields are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'Children\u2019s Oncology Group (COG)\\' is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'SIOP\u22122001 randomized trial\\' is referenced in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'UKW3 trial\\' is referenced in the document \\'sample.pdf\\'.\",\\n    \"The \\'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)\\' is mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours are referenced in the document \\'sample.pdf\\'.\",\\n    \"Event-free survival (EFS) and overall survival metrics are discussed in the document \\'sample.pdf\\'.\",\\n    \"Stage IV disease is referenced in the document \\'sample.pdf\\'.\",\\n    \"The \\'CT at week 10\\' is mentioned in a procedure context in the document \\'sample.pdf\\'.\",\\n    \"Nephron-sparing surgery (NSS) is a surgical technique mentioned in the document \\'sample.pdf\\'.\",\\n    \"Laparoscopic surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"The document mentions bilateral Wilms tumour and its relation to ESRD and WAGR syndrome.\",\\n    \"The document discusses treatments including high-dose chemotherapy and autologous stem cell transplantation.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to the UMBRELLA SIOP\u2013RTSG 2016 protocol.\",\\n    \"Renal tumour patients is a group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.14285714285714285, reason=\"The score is 0.14 because the only relevant statement about 'Chest CT is used in the detection of pulmonary nodules' does not address imaging modalities specifically for staging, while the reasons for irrelevancy highlight a consistent lack of direct reference to imaging modalities.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031432499999999998, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA protocol is a treatment protocol for renal tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement does not specifically mention any imaging modality for staging.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol includes various treatment methodologies.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"It focuses on treatment methodologies rather than imaging modalities.\"\\n            },\\n            {\\n                \"statement\": \"Chest CT is used in the detection of pulmonary nodules.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol emphasizes the importance of lymph node sampling.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The focus is on sampling procedures, not on imaging modalities for staging.\"\\n            },\\n            {\\n                \"statement\": \"The protocol documents various clinical trials involving different treatments for Wilms tumour.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"No reference to imaging modalities for staging is provided.\"\\n            },\\n            {\\n                \"statement\": \"Pulmonary radiotherapy is mentioned in relation to treatment during the study.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"It discusses treatment not specifically imaging modalities.\"\\n            },\\n            {\\n                \"statement\": \"Various countries are involved in the UMBRELLA protocol implementation.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement does not relate to imaging modalities.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What imaging modality is mentioned for staging in the UMBRELLA protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Chest CT is mentioned for staging, particularly to detect small pulmonary nodules.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_8', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=True, score=0.9917578064362983, reason='The actual output lists vincristine, actinomycin D, and doxorubicin, which align with the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028400999999999995, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0072207, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP-RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to SIOP-RTSG.\",\\n    \"Renal tumour patients is a group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a clinical protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u20132001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"The SIOP\u22122001 randomized controlled trial studies outcomes related to drugs and treatments.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"The COG protocol is a clinical protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Doxorubicin, vincristine and actinomycin D is a treatment regimen.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The high-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"SIOP Renal Tumour Study Group (SIOP-RTSG) is a group.\",\\n    \"SIOP WT 2001 is a protocol.\",\\n    \"National Wilms\u2019 Tumor Study is a study.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document sample.pdf.\",\\n    \"Janna A. Hol is an author associated with the document sample.pdf.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document sample.pdf.\",\\n    \"Harm van Tinteren is an author associated with the document sample.pdf.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document sample.pdf.\",\\n    \"Arnauld C. Verschuur is an author associated with the document sample.pdf.\",\\n    \"Gordan M. Vujanic is an author associated with the document sample.pdf.\",\\n    \"Ivo Leuschner is an author associated with the document sample.pdf.\",\\n    \"Jesper Brok is an author associated with the document sample.pdf.\",\\n    \"Christian R\u00fcbe is an author associated with the document sample.pdf.\",\\n    \"Anne M. Smets is an author associated with the document sample.pdf.\",\\n    \"Geert O. Janssens is an author associated with the document sample.pdf.\",\\n    \"Jan Godzinski is an author associated with the document sample.pdf.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document sample.pdf.\",\\n    \"Beatriz de Camargo is an author associated with the document sample.pdf.\",\\n    \"Heidi Segers is an author associated with the document sample.pdf.\",\\n    \"Paola Collini is an author associated with the document sample.pdf.\",\\n    \"Manfred Gessler is an author associated with the document sample.pdf.\",\\n    \"Christophe Bergeron is an author associated with the document sample.pdf.\",\\n    \"Filippo Spreafico is an author associated with the document sample.pdf.\",\\n    \"Norbert Graf is an author associated with the document sample.pdf.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document sample.pdf.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document sample.pdf.\",\\n    \"Wilms tumour is a disease associated with the document sample.pdf.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol associated with the document sample.pdf.\",\\n    \"Childhood renal tumours is a disease associated with the document sample.pdf.\",\\n    \"The SIOP\u20132001 protocol is a protocol associated with the document sample.pdf.\",\\n    \"1q is a genomic change associated with the document sample.pdf.\",\\n    \"The website www.siop-rtsg.eu is associated with the document sample.pdf.\",\\n    \"Renal tumour patients is a patient group associated with the document sample.pdf.\",\\n    \"The Consensus Statement is a document associated with the sample.pdf.\",\\n    \"Wilms tumours is a disease associated with the document sample.pdf.\",\\n    \"The UMBRELLA protocol is a protocol associated with the document sample.pdf.\",\\n    \"Diagnostics is a field associated with the document sample.pdf.\",\\n    \"Treatment is a field associated with the document sample.pdf.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization associated with the document sample.pdf.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial associated with the document sample.pdf.\",\\n    \"Doxorubicin is a drug associated with the document sample.pdf.\",\\n    \"Actinomycin D is a drug associated with the document sample.pdf.\",\\n    \"Vincristine is a drug associated with the document sample.pdf.\",\\n    \"The UKW3 trial is a clinical trial associated with the document sample.pdf.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization associated with the document sample.pdf.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype associated with the document sample.pdf.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.6, reason=\"The score is 0.60 because although there are relevant mentions such as 'doxorubicin' and 'actinomycin D', the context fails to provide a comprehensive list or direct answers regarding specific chemotherapy agents, as highlighted by the statements on the lack of specificity.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0032139, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"doxorubicin\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"actinomycin D\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"vincristine\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"vincristine, actinomycin D plus doxorubicin\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"vincristine and actinomycin D without doxorubicin\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context mentions \\'vincristine and actinomycin D without doxorubicin\\', which is related but does not directly answer the question about chemotherapy agents being mentioned.\"\\n            },\\n            {\\n                \"statement\": \"high-dose chemotherapy and autologous stem cell transplantation\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The mention of \\'high-dose chemotherapy and autologous stem cell transplantation\\' does not specify it as an individual chemotherapy agent.\"\\n            },\\n            {\\n                \"statement\": \"four-drug regimen\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement \\'four-drug regimen\\' refers to a combination treatment but does not specify which agents are part of it.\"\\n            },\\n            {\\n                \"statement\": \"camptothecins\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While \\'camptothecins\\' is a type of treatment, it doesn\\'t specify the exact chemotherapy agent.\"\\n            },\\n            {\\n                \"statement\": \"irinotecan\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"topotecan\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What specific chemotherapy agents are mentioned in the treatment recommendations?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Agents such as vincristine, actinomycin D, doxorubicin, and in some cases etoposide and cyclophosphamide are mentioned.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_17', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.07765523784800756, reason='The actual output does not address survival rates or treatment improvements mentioned in the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00283245, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00717855, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP-RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP-2001 protocol is a protocol.\",\\n    \"1q refers to a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to SIOP-RTSG.\",\\n    \"Renal tumour patients are a patient group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours are a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 refers to a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed tumours are a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"Blastemal-type tumours are a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"Congenital mesoblastic nephroma is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"The SIOP database is a database.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP-9/GPOH refers to a trial.\",\\n    \"Proton therapy is a treatment.\",\\n    \"CT-only nodules are a medical condition.\",\\n    \"Nephrectomy is a surgical procedure.\",\\n    \"SIOP Renal Tumour Study Group (SIOP-RTSG) is a group.\",\\n    \"The SIOP Pathology Panel is a panel.\",\\n    \"Daw, N. C. is an author.\",\\n    \"Furtwangler, R. is an author.\",\\n    \"Weirich, A. is an author.\",\\n    \"Terenziani, M. is an author.\",\\n    \"Ha, T. C. is an author.\",\\n    \"Kremens, B. is an author.\",\\n    \"The National Wilms\u2019 Tumor Study is a study.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document sample.pdf.\",\\n    \"Janna A. Hol is an author associated with the document sample.pdf.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document sample.pdf.\",\\n    \"Harm van Tinteren is an author associated with the document sample.pdf.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document sample.pdf.\",\\n    \"Arnauld C. Verschuur is an author associated with the document sample.pdf.\",\\n    \"Gordan M. Vujanic is an author associated with the document sample.pdf.\",\\n    \"Ivo Leuschner is an author associated with the document sample.pdf.\",\\n    \"Jesper Brok is an author associated with the document sample.pdf.\",\\n    \"Christian R\u00fcbe is an author associated with the document sample.pdf.\",\\n    \"Anne M. Smets is an author associated with the document sample.pdf.\",\\n    \"Geert O. Janssens is an author associated with the document sample.pdf.\",\\n    \"Jan Godzinski is an author associated with the document sample.pdf.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document sample.pdf.\",\\n    \"Beatriz de Camargo is an author associated with the document sample.pdf.\",\\n    \"Heidi Segers is an author associated with the document sample.pdf.\",\\n    \"Paola Collini is an author associated with the document sample.pdf.\",\\n    \"Manfred Gessler is an author associated with the document sample.pdf.\",\\n    \"Christophe Bergeron is an author associated with the document sample.pdf.\",\\n    \"Filippo Spreafico is an author associated with the document sample.pdf.\",\\n    \"Norbert Graf is an author associated with the document sample.pdf.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document sample.pdf.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document sample.pdf.\",\\n    \"Wilms tumour is a disease mentioned in the document sample.pdf.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the document sample.pdf.\",\\n    \"Childhood renal tumours are a disease mentioned in the document sample.pdf.\",\\n    \"The SIOP-2001 protocol is a protocol mentioned in the document sample.pdf.\",\\n    \"1q is a genomic change mentioned in the document sample.pdf.\",\\n    \"The website www.siop-rtsg.eu is mentioned in the document sample.pdf.\",\\n    \"Renal tumour patients are a group mentioned in the document sample.pdf.\",\\n    \"A Consensus Statement document is referenced in the document sample.pdf.\",\\n    \"Wilms tumours are a disease mentioned in the document sample.pdf.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document sample.pdf.\",\\n    \"Diagnostics and treatment are fields mentioned in the document sample.pdf.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization mentioned in the document sample.pdf.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the document sample.pdf.\",\\n    \"Doxorubicin is a drug mentioned in the document sample.pdf.\",\\n    \"Actinomycin D is a drug mentioned in the document sample.pdf.\",\\n    \"Vincristine is a drug mentioned in the document sample.pdf.\",\\n    \"The UKW3 trial is a clinical trial mentioned in the document sample.pdf.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization mentioned in the document sample.pdf.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document sample.pdf.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study mentioned in the document sample.pdf.\",\\n    \"CT-only nodules are a medical condition mentioned in the document sample.pdf.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.625, reason=\"The score is 0.62 because while some relevant statements indicate that 'the study evaluates event-free survival (EFS) and overall survival rates (OS) for various treatments', many other statements focus on protocol details or eligibility, failing to directly address expected outcomes. This disconnect leads to a moderate relevancy score.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00319905, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"Wilms tumour is addressed in the UMBRELLA protocol, which provides guidelines for treatment.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement details the protocol but does not provide expected outcomes.\"\\n            },\\n            {\\n                \"statement\": \"High-risk blastemal-type Wilms tumours are part of the study parameters for expected outcomes in patients.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol includes treatment for Wilms tumors.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement mentions treatment protocols but does not answer about expected outcomes.\"\\n            },\\n            {\\n                \"statement\": \"Patients with large-volume tumours have distinct survival outcomes depending on treatment protocols in Wilms tumour management.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The study evaluates event-free survival (EFS) and overall survival rates (OS) for various treatments.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The document talks about eligibility and guidelines for participating in various trials.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement focuses on eligibility and does not address patient outcomes.\"\\n            },\\n            {\\n                \"statement\": \"Children\\'s Oncology Group studies and SIOP trials include many patients with Wilms tumour, impacting statistical outcomes.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Diagnosis and treatment stratification based on risk levels influence prognosis and management of Wilms tumour.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What are the expected outcomes for patients with Wilms tumour under this protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Survival rates are expected to be high, with improvements in event-free and overall survival due to standardized treatment approaches.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_14', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=True, score=0.9968187210909847, reason='The actual output correctly identifies the International Society of Paediatric Oncology (SIOP\u2013RTSG) as the developer of the UMBRELLA protocol.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028415999999999997, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=0.88, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00717375, verbose_logs='Truths (limit=None):\\n[\\n    \"The document titled \\'sample.pdf\\' contains contributions from various authors.\",\\n    \"Marry M. van den Heuvel-Eibrink is one of the authors.\",\\n    \"Janna A. Hol is one of the authors.\",\\n    \"Kathy Pritchard-Jones is one of the authors.\",\\n    \"Harm van Tinteren is one of the authors.\",\\n    \"Rhoikos Furtw\u00e4ngler is one of the authors.\",\\n    \"Arnauld C. Verschuur is one of the authors.\",\\n    \"Gordan M. Vujanic is one of the authors.\",\\n    \"Ivo Leuschner is one of the authors.\",\\n    \"Jesper Brok is one of the authors.\",\\n    \"Christian R\u00fcbe is one of the authors.\",\\n    \"Anne M. Smets is one of the authors.\",\\n    \"Geert O. Janssens is one of the authors.\",\\n    \"Jan Godzinski is one of the authors.\",\\n    \"Gema L. Ram\u00edrez-Villar is one of the authors.\",\\n    \"Beatriz de Camargo is one of the authors.\",\\n    \"Heidi Segers is one of the authors.\",\\n    \"Paola Collini is one of the authors.\",\\n    \"Manfred Gessler is one of the authors.\",\\n    \"Christophe Bergeron is one of the authors.\",\\n    \"Filippo Spreafico is one of the authors.\",\\n    \"Norbert Graf is one of the authors.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization involved in the study.\",\\n    \"SIOP\u2013RTSG is an organization associated with this document.\",\\n    \"Wilms tumour is a disease discussed in this document.\",\\n    \"Childhood renal tumours are mentioned as a type of disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is referenced in the document as a clinical protocol.\",\\n    \"The SIOP\u20132001 protocol is referenced in the document as a clinical protocol.\",\\n    \"The genomic change \\'1q\\' is discussed in the document.\",\\n    \"The website www.siop-rtsg.eu is mentioned in the document.\",\\n    \"The renal tumour patients group is mentioned in relation to the document.\",\\n    \"A Consensus Statement document is referenced in the text.\",\\n    \"The document discusses Wilms tumours as a specific disease.\",\\n    \"The UMBRELLA protocol is mentioned in relation to clinical guidelines.\",\\n    \"The fields of diagnostics and treatment are topics covered in the document.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization referenced in this document.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in this document.\",\\n    \"Doxorubicin, actinomycin D, and vincristine are drugs mentioned in the text.\",\\n    \"The UKW3 trial is a clinical trial referenced in this document.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization involved in this context.\",\\n    \"High-risk, blastemal-type Wilms tumours are referenced in the document.\",\\n    \"Event-free survival (EFS) and overall survival are medical metrics discussed in the document, indicating outcomes related to the treatments studied.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author of the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author of the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author of the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author of the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author of the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author of the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author of the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author of the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author of the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author of the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author of the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author of the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author of the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author of the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author of the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author of the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author of the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author of the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author of the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author of the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author of the document \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour and childhood renal tumours are diseases associated with the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol associated with the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u20132001 protocol is another protocol associated with the document \\'sample.pdf\\'.\",\\n    \"1q is a genomic change associated with the document \\'sample.pdf\\'.\",\\n    \"The website www.siop-rtsg.eu is associated with the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients are a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The \\'Consensus Statement\\' is a document mentioned in the text.\",\\n    \"Wilms tumours is a disease that appears in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is also mentioned in the document \\'sample.pdf\\'.\",\\n    \"The fields of diagnostics and treatment are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin, actinomycin D, and vincristine are drugs mentioned in connection with the document \\'sample.pdf\\'.\",\\n    \"UKW3 trial is a clinical trial referenced in the document \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype discussed in the document \\'sample.pdf\\'.\",\\n    \"An event-free survival (EFS) metric is discussed in relation to the document \\'sample.pdf\\'.\",\\n    \"Overall survival is another medical metric referenced in the document \\'sample.pdf\\'.\",\\n    \"The SIOP-2001 clinical trial is mentioned within the document \\'sample.pdf\\'.\",\\n    \"Large-volume tumours are a medical condition referenced in the document \\'sample.pdf\\'.\",\\n    \"Stromal tumour types and epithelial tumour types are also medical conditions referenced in the document \\'sample.pdf\\'.\",\\n    \"Focal anaplasia-type tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that large-volume tumours are referenced in the document \\'sample.pdf\\', but this specific term is not mentioned in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim refers to stromal tumour types and epithelial tumour types as referenced in the document \\'sample.pdf\\', but these specific terms are not included in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that focal anaplasia-type tumours are mentioned in the document \\'sample.pdf\\', but this specific type of tumour is not noted in the retrieval context.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.0, reason=\"The score is 0.00 because the retrieval context does not contain any relevant information addressing which international society is responsible for the protocol. All reasons stated indicate a lack of specificity and relevance, such as 'it simply states a fact without supporting details' and 'fails to answer which society is specifically responsible for the protocol'.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0032131499999999997, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is responsible for the protocol.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement does not provide direct information about which international society is responsible for the protocol; it simply states a fact without supporting details.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol follows the guidelines established by several international organizations.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While it mentions organizations, it doesn\\'t specifically identify which international society is responsible for the protocol requested.\"\\n            },\\n            {\\n                \"statement\": \"SIOP\\\\u2013RTSG is one of the organizations involved in pediatric oncology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement mentions an organization related to pediatric oncology, but it does not clarify if it is the responsible one for the protocol.\"\\n            },\\n            {\\n                \"statement\": \"Children\\\\u2019s Oncology Group (COG) is another organization that operates in the field of pediatric oncology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement presents information about COG but fails to answer which society is specifically responsible for the protocol.\"\\n            },\\n            {\\n                \"statement\": \"The correspondence of organizations and protocols in pediatric oncology involves multiple international agencies.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This is too vague and does not specify a single international society responsible for the protocol.\"\\n            },\\n            {\\n                \"statement\": \"Various countries are collaborating on diagnoses and treatments for Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This information does not directly relate to the question of which organization is responsible.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol is a treatment protocol standardized by several international collaborations.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement mentions collaborations but does not specify which particular international society is indicated for responsibility.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='Which international society is responsible for the protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='The International Society of Paediatric Oncology (SIOP\u2013RTSG) developed the UMBRELLA protocol.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_7', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.16527021432446382, reason='The actual output lists various documents and authors but does not provide a coherent recommendation or mention the structured approach related to chemotherapy and stem cell rescue as expected.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028411499999999998, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00749505, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours are a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"The 1q genomic change is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to SIOP\u2013RTSG.\",\\n    \"Renal tumour patients are a patient group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours are a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours are a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 randomized trial is a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours are a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules are a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol includes CCSK, MRTK, CMN, RCC as medical conditions it includes treatment for.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is developed by the International Society of Paediatric Oncology \u2013 Renal Tumour Study Group.\",\\n    \"Wilms tumour affects adult patients.\",\\n    \"Wilms tumour includes infant Wilms tumours.\",\\n    \"The UMBRELLA protocol guides treatment for Wilms tumours.\",\\n    \"The UMBRELLA protocol includes CT-only nodules.\",\\n    \"The UMBRELLA protocol defines treatment for Group AA, Group BB, Group CC.\",\\n    \"The UMBRELLA protocol provides guidelines for surgery and radiotherapy.\",\\n    \"SIOP-2001 randomized controlled trial investigates doxorubicin.\",\\n    \"Doxorubicin is included in the UMBRELLA protocol.\",\\n    \"Doxorubicin is used in chemotherapy.\",\\n    \"Event-free survival (EFS) is associated with large-volume tumours.\",\\n    \"Large-volume tumours are a subset of stage II\u2013III regressive, mixed, and focal anaplasia-type tumours.\",\\n    \"Metastatic disease is associated with stage IV disease.\",\\n    \"COG protocol includes CT-only nodules.\",\\n    \"SIOP\u22122001 considers high-dose chemotherapy and autologous stem cell transplantation.\",\\n    \"AREN0533 studies high-dose chemotherapy and autologous stem cell transplantation.\",\\n    \"SIOP database captures outcomes of high-dose chemotherapy and autologous stem cell transplantation.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to the SIOP\u2013RTSG.\",\\n    \"Renal tumour patients is a group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a clinical protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"SIOP\u22122001 is a clinical trial.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"Event-free survival (EFS) is an entity.\",\\n    \"Large-volume tumours is an entity.\",\\n    \"Stage II\u2013III regressive, mixed, and focal anaplasia-type tumours is an entity.\",\\n    \"Metastatic disease is an entity.\",\\n    \"Stage IV disease is an entity.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Adult Wilms\u2019 tumour is a condition.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.8, reason=\"The score is 0.80 because although there is a significant amount of relevant information about 'high dose therapy in recurrent Wilms\u2019 tumour_treatment' and 'autologous stem cell rescue (ASCR)_Treatment,' the presence of irrelevant statements like 'rumors about Wilms tumour_disease' detracts from the overall context, preventing a perfect score.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0030876000000000002, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"relapsed group CC_Patient Group\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"high dose therapy in recurrent Wilms\\\\u2019 tumour_treatment\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"autologous stem cell rescue (ASCR)_Treatment\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"high-risk blastemal-type Wilms tumour_condition\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"rumors about Wilms tumour_disease\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement \\'rumors about Wilms tumour_disease\\' does not address the treatment of relapsed Wilms tumour.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How does the protocol address the treatment of relapsed Wilms tumour?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='It recommends a structured approach that may include combinations of chemotherapy agents and, in some cases, high-dose chemotherapy with autologous stem cell rescue.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_19', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output contains a list of entities and relations rather than a summary of the effects of standardization on patient data, missing the key points regarding homogeneous patient data, prognostic assessments, and research opportunities.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00284715, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0074343, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to the SIOP\u2013RTSG.\",\\n    \"Renal tumour patients are a patient group.\",\\n    \"A Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a clinical protocol.\",\\n    \"Diagnostics is a field related to medical practice.\",\\n    \"Treatment is a field related to medical practice.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u20132001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK, MRTK, CMN, RCC are medical conditions associated with Wilms tumour.\",\\n    \"Proton therapy is a treatment for Wilms tumour.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author of the document.\",\\n    \"Janna A. Hol is an author of the document.\",\\n    \"Kathy Pritchard-Jones is an author of the document.\",\\n    \"Harm van Tinteren is an author of the document.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author of the document.\",\\n    \"Arnauld C. Verschuur is an author of the document.\",\\n    \"Gordan M. Vujanic is an author of the document.\",\\n    \"Ivo Leuschner is an author of the document.\",\\n    \"Jesper Brok is an author of the document.\",\\n    \"Christian R\u00fcbe is an author of the document.\",\\n    \"Anne M. Smets is an author of the document.\",\\n    \"Geert O. Janssens is an author of the document.\",\\n    \"Jan Godzinski is an author of the document.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author of the document.\",\\n    \"Beatriz de Camargo is an author of the document.\",\\n    \"Heidi Segers is an author of the document.\",\\n    \"Paola Collini is an author of the document.\",\\n    \"Manfred Gessler is an author of the document.\",\\n    \"Christophe Bergeron is an author of the document.\",\\n    \"Filippo Spreafico is an author of the document.\",\\n    \"Norbert Graf is an author of the document.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is available.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.16666666666666666, reason=\"The score is 0.17 because most statements in the retrieval context focus on specific protocols and guidelines without addressing the broader intended benefits of standardizing treatment for renal tumours, as seen in 'The focus of the statement is on a specific protocol rather than the intended benefits of standardizing treatment for renal tumours.' The only relevant statement discusses an organization's goal but does not explain the benefits, leading to a low relevance score.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00317415, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is a treatment protocol for Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The focus of the statement is on a specific protocol rather than the intended benefits of standardizing treatment for renal tumours.\"\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol provides guidelines for surgery and radiotherapy.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement discusses guidelines rather than specifically addressing the benefits of standardization.\"\\n            },\\n            {\\n                \"statement\": \"High-risk blastemal-type Wilms tumours are included in the SIOP\\\\u2013RTSG 2016 protocol.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This relates to a specific tumour subtype and protocol but does not address the broader benefits of standardization.\"\\n            },\\n            {\\n                \"statement\": \"Event-free survival (EFS) is evaluated in the SIOP\\\\u22122001 randomized controlled trial.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While EFS is a relevant metric, this statement does not directly discuss the intended benefits of standardizing treatments.\"\\n            },\\n            {\\n                \"statement\": \"The International Society of Paediatric Oncology aims to standardize treatment approaches.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Consensus Statement targets renal tumour patients.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"Although it targets patients, it does not explain the intended benefits of standardization.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What is the intended benefit of standardizing treatment for renal tumours?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Standardization should lead to more homogeneous patient data, better prognostic assessments, and improved opportunities for future research and clinical trials.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_13', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output provides a list of entities and relationships but does not address the factual correctness of the expected output, which is about prospective data collection from patients.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00283935, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=0.8529411764705882, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0076437, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the study of Wilms tumour.\",\\n    \"Janna A. Hol is an author associated with the study of Wilms tumour.\",\\n    \"Kathy Pritchard-Jones is an author associated with the study of Wilms tumour.\",\\n    \"Harm van Tinteren is an author associated with the study of Wilms tumour.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the study of Wilms tumour.\",\\n    \"Arnauld C. Verschuur is an author associated with the study of Wilms tumour.\",\\n    \"Gordan M. Vujanic is an author associated with the study of Wilms tumour.\",\\n    \"Ivo Leuschner is an author associated with the study of Wilms tumour.\",\\n    \"Jesper Brok is an author associated with the study of Wilms tumour.\",\\n    \"Christian R\u00fcbe is an author associated with the study of Wilms tumour.\",\\n    \"Anne M. Smets is an author associated with the study of Wilms tumour.\",\\n    \"Geert O. Janssens is an author associated with the study of Wilms tumour.\",\\n    \"Jan Godzinski is an author associated with the study of Wilms tumour.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the study of Wilms tumour.\",\\n    \"Beatriz de Camargo is an author associated with the study of Wilms tumour.\",\\n    \"Heidi Segers is an author associated with the study of Wilms tumour.\",\\n    \"Paola Collini is an author associated with the study of Wilms tumour.\",\\n    \"Manfred Gessler is an author associated with the study of Wilms tumour.\",\\n    \"Christophe Bergeron is an author associated with the study of Wilms tumour.\",\\n    \"Filippo Spreafico is an author associated with the study of Wilms tumour.\",\\n    \"Norbert Graf is an author associated with the study of Wilms tumour.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization focused on renal tumours.\",\\n    \"SIOP\u2013RTSG is an organization focused on pediatric renal tumours.\",\\n    \"Wilms tumour is a type of childhood renal tumour.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol pertains to the treatment of Wilms tumour.\",\\n    \"The SIOP\u20132001 protocol is related to the treatment of Wilms tumour.\",\\n    \"1q is a genomic change associated with Wilms tumour.\",\\n    \"The website www.siop-rtsg.eu pertains to the SIOP\u2013RTSG.\",\\n    \"Renal tumour patients are a specific patient group.\",\\n    \"The Consensus Statement document discusses treatment approaches for renal tumours.\",\\n    \"Wilms tumours are a subtype of Wilms tumour.\",\\n    \"The UMBRELLA protocol relates to Wilms tumours treatment.\",\\n    \"The fields of diagnostics and treatment are crucial for Wilms tumour.\",\\n    \"The Children\u2019s Oncology Group (COG) is focused on child cancer and conducts studies.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial related to Wilms tumour.\",\\n    \"Doxorubicin, actinomycin D, and vincristine are drugs used in the treatment of Wilms tumour.\",\\n    \"The UKW3 trial is a clinical trial associated with Wilms tumour treatment.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) focuses on childhood cancer.\",\\n    \"High-risk, blastemal-type Wilms tumours are a category within Wilms tumours.\",\\n    \"The event-free survival (EFS) and overall survival metrics are important in assessing Wilms tumour treatment outcomes.\",\\n    \"SIOP-2001 is a clinical trial investigating Wilms tumour.\",\\n    \"Large-volume tumours and various types of tumours are categorized under medical conditions relating to childhood renal tumours.\",\\n    \"The chest CT is a diagnostic test used for detecting pulmonary nodules associated with Wilms tumour.\",\\n    \"Chemotherapeutic regimens for Wilms tumour may include doxorubicin, actinomycin D, and vincristine.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation are treatment options for Wilms tumour.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a new protocol concerning Wilms tumour treatment.\",\\n    \"Nephrectomy is a surgical procedure relevant in managing Wilms tumour.\",\\n    \"The SIOP database captures outcomes related to Wilms tumour studies.\",\\n    \"Radiotherapy and chemotherapy are common treatment modalities for Wilms tumour who are at various risk levels.\",\\n    \"The high-risk, blastemal-type Wilms tumours are associated with poor prognosis.\",\\n    \"Iceland, Germany, Italy, Netherlands, Poland, Austria, France, Spain, and the UK are countries conducting research on Wilms tumour.\",\\n    \"The ExPO-r-Net project is directly related to advancements in childhood cancer treatments.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"www.siop-rtsg.eu is a website.\",\\n    \"Renal tumour patients is a group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Adult Wilms\u2019 tumor is a condition.\",\\n    \"SIOP\u2013RTSG panel is an entity.\",\\n    \"SIOP-9/GPOH trial is a clinical trial.\",\\n    \"National Wilms\u2019 Tumor Study is a study.\",\\n    \"SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that Wilms tumours is a disease, which is inaccurate as Wilms tumour is a type of childhood renal tumour.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that the UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is a protocol, while the retrieval context describes it as related specifically to the treatment of Wilms tumour.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that childhood renal tumours is a disease, while it is more accurately described as a category of conditions.\"\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that renal tumour patients is a group, but the context does not define it as a specific group, only mentioning that they are a specific patient population.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states that the Consensus Statement is a document, however, that might imply it\\'s a standalone document unrelated to the context of renal tumours, which is not confirmed.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.0, reason=\"The score is 0.00 because there are no relevant statements in the retrieval context that address the monitoring of long-term outcomes, as highlighted by the reasons such as 'The context does not contain specific details about monitoring long-term outcomes of the protocol.' and 'The statement does not provide any details regarding the monitoring of long-term outcomes, just identifies the protocol.'.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00311445, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"How does the protocol plan to monitor long-term outcomes?\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context does not contain specific details about monitoring long-term outcomes of the protocol.\"\\n            },\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is a clinical protocol.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement does not provide any details regarding the monitoring of long-term outcomes, just identifies the protocol.\"\\n            },\\n            {\\n                \"statement\": \"SIOP-2001 randomized trial evaluates EFS probability and OS probability.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement relates to evaluating survival probabilities rather than monitoring long-term outcomes.\"\\n            },\\n            {\\n                \"statement\": \"SIOP\\\\u2212RTSG standardizes methodologies across involved studies.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement describes standardization but does not mention monitoring of long-term outcomes.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol provides guidelines for treatment.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement focuses on guidelines and does not address monitoring long-term outcomes.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How does the protocol plan to monitor long-term outcomes?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='By collecting comprehensive, prospective data from a large cohort of patients.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_4', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output does not present any information regarding tumor volume, patient stratification, or treatment intensity, which are central to the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028396499999999996, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=0.8823529411764706, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0074802, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is associated with the SIOP\u2013RTSG.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP\u22122001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"The event-free survival probability is a metric.\",\\n    \"The overall survival probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"The HR is a statistic.\",\\n    \"The Log\u2013Rank P is a statistic.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"The COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The SIOP database is a database.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Wilms tumour is a disease.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"The confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"The SIOP\u2013RTSG is an organization.\",\\n    \"The innovative therapies for children with cancer consortium is an organization.\",\\n    \"The questionnaire is a document.\",\\n    \"SIOP-9/GPOH is a trial.\",\\n    \"Adult Wilms\u2019 tumor is a condition.\",\\n    \"The Consensus Statement targets renal tumour patients.\",\\n    \"Vincristine is included in postoperative chemotherapy.\",\\n    \"Actinomycin D is included in postoperative chemotherapy.\",\\n    \"The UKW3 trial supports the use of actinomycin D.\",\\n    \"The UKW3 trial supports the use of vincristine.\",\\n    \"Vincristine and actinomycin D without doxorubicin is used in SIOP-2001.\",\\n    \"Stromal and epithelial tumor types have an excellent prognosis.\",\\n    \"Blastemal-type tumours are compared in the SIOP-2001 and SIOP\u221293\u201301.\",\\n    \"Chest CT detects pulmonary nodules.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol includes treatment for CCSK, MRTK, CMN, and RCC.\",\\n    \"The SIOP\u22122001 randomized controlled trial evaluates EFS probability.\",\\n    \"The SIOP\u22122001 randomized controlled trial evaluates OS probability.\",\\n    \"60-month EFS \u2013 500+ ml contributes to EFS probability.\",\\n    \"60-month OS \u2013 500+ ml contributes to OS probability.\",\\n    \"The NWTS-4 trial tested vincristine, actinomycin D plus doxorubicin.\",\\n    \"The NWTS-5 trial tested vincristine, actinomycin D plus doxorubicin.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is associated with 60-month OS \u2013 AVD. <500 ml.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is associated with 60-month EFS \u2013 AVD. <500 ml.\"\\n] \\n \\nClaims:\\n[\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is associated with Wilms tumour.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is associated with childhood renal tumours.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is associated with the SIOP\u20132001 protocol.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is available on www.siop-rtsg.eu.\",\\n    \"Wilms tumour affects both adult patients and infants.\",\\n    \"Wilms tumour is a subject of the UMBRELLA SIOP\u2013RTSG 2016 protocol.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group developed the UMBRELLA SIOP\u2013RTSG 2016 protocol.\",\\n    \"Marry M. van den Heuvel-Eibrink, Janna A. Hol, Kathy Pritchard-Jones, Harm van Tinteren, Rhoikos Furtw\u00e4ngler, Arnauld C. Verschuur, Gordan M. Vujanic, Ivo Leuschner, Jesper Brok, Christian R\u00fcbe, Anne M. Smets, Geert O. Janssens, Jan Godzinski, Gema L. Ram\u00edrez-Villar, Beatriz de Camargo, Heidi Segers and Paola Collini are all authors associated with the document sample.pdf.\",\\n    \"Wilms tumour is related to the diagnosis and treatment of childhood renal tumours.\",\\n    \"The SIOP\u20132001 protocol is a clinical protocol linked to childhood renal tumours.\",\\n    \"The SIOP\u20132001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin, actinomycin D and vincristine are drugs related to Wilms tumour treatment.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization related to Wilms tumour treatment studies.\",\\n    \"High-risk, blastemal-type Wilms tumours refer to a specific subtype of Wilms tumour.\",\\n    \"The UKW3 trial is a clinical trial related to Wilms tumour.\",\\n    \"The data shared about outcomes includes event-free survival (EFS) and overall survival metrics.\",\\n    \"Renal tumour patients are a specific group targeted for treatments outlined in the Consensus Statement document.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is not associated with the SIOP\\\\u20132001 protocol as they are distinct protocols according to the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"Wilms tumour does not affect adult patients, it primarily affects children as stated in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.6363636363636364, reason=\"The score is 0.64 because, while relevant statements like 'The UMBRELLA SIOP-RTSG 2016 protocol provides guidelines for the treatment of Wilms tumours' have some connection to treatment guidelines, many irrelevant statements\u2014such as those discussing 'survival rates for high-risk Wilms tumours'\u2014detract from the focus on tumor volume significance, indicating a moderate level of relevance.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0033644999999999994, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"The UMBRELLA SIOP-RTSG 2016 protocol provides guidelines for the treatment of Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The SIOP-2001 protocol is subject to the childhood renal tumours treatment guidelines.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Large-volume tumours are treated with doxorubicin and other chemotherapy drugs.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumours and their treatment options are structured under various protocols including the SIOP\\\\u20132001 and UMBRELLA protocols.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"European countries are involved in the study and treatment of childhood renal tumours, evidenced by multiple protocols and collaborations.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Adverse outcomes in childhood cancers can be enhanced by chemotherapy-resistant disease, necessitating further research.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"SIOP database captures the outcomes of various treatment protocols for Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The survival rates for high-risk Wilms tumours are documented but do not specify their significance in treatment guidelines.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement mentions \\'survival rates for high-risk Wilms tumours\\', which does not directly address the significance of tumor volume in treatment guidelines.\"\\n            },\\n            {\\n                \"statement\": \"No evidence of viable or necrotic tumours can be confirmed through histological procedures.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement focuses on histological confirmations, not on tumor volume\\'s significance in treatment guidelines.\"\\n            },\\n            {\\n                \"statement\": \"Chest CT is a diagnostic tool used in detecting pulmonary nodules associated with various conditions.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement refers to \\'diagnostic tools\\' and \\'pulmonary nodules\\', which do not relate to tumor volume significance in treatment guidelines.\"\\n            },\\n            {\\n                \"statement\": \"Chemotherapy medications like carboplatin and etoposide are used in treating advanced cancers.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement mentions \\'chemotherapy medications\\' and \\'advanced cancers\\', missing connection to the specific topic of \\'tumor volume significance\\'.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What is the significance of tumor volume in the treatment guidelines?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Tumor volume is used to stratify patients and guide treatment intensity, especially regarding the use of chemotherapy agents like doxorubicin.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_6', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output does not mention radiotherapy or its application for metastatic sites or surgical resection, thus it does not align with the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00283935, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.007806899999999999, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"www.siop-rtsg.eu is a website.\",\\n    \"Renal tumour patients is a group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics and treatment refer to fields.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"The 60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"The 60-month OS \u2013 <500 ml is an outcome.\",\\n    \"The 60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"The 60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"The COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The SIOP\u22122001 is a protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The SIOP database is a database.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135 mm is a disease characteristic.\",\\n    \"Lung nodules >5 mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"The confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Iceland is a country.\",\\n    \"Germany is a country.\",\\n    \"Italy is a country.\",\\n    \"The Netherlands is a country.\",\\n    \"Poland is a country.\",\\n    \"Austria is a country.\",\\n    \"France is a country.\",\\n    \"Spain is a country.\",\\n    \"The UK is a country.\",\\n    \"Weirich, A. is an author.\",\\n    \"The Children\u2019s Oncology Group study AREN0533 is a study.\",\\n    \"The SIOP-9/GPOH is a trial.\",\\n    \"Terenziani, M. is an author.\",\\n    \"Adult Wilms\u2019 tumour is a condition.\",\\n    \"Daw, N. C. is an author.\",\\n    \"Vincristine and irinotecan is a treatment.\",\\n    \"The Children\u2019s Oncology Group AREN0321 is a study.\",\\n    \"Ha, T. C. is an author.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is a treatment.\",\\n    \"Kremens, B. is an author.\",\\n    \"Autologous stem cell rescue is a treatment.\",\\n    \"Furtwangler, R. is an author.\",\\n    \"The GPOH-nephroblastoma study group is a group.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is a group.\",\\n    \"The SIOP WT 2001 is a protocol.\",\\n    \"D\u2019Angio, G. J. is an author.\",\\n    \"The National Wilms\u2019 Tumor Study is a study.\",\\n    \"The SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the sample.pdf document.\",\\n    \"Janna A. Hol is an author associated with the sample.pdf document.\",\\n    \"Kathy Pritchard-Jones is an author associated with the sample.pdf document.\",\\n    \"Harm van Tinteren is an author associated with the sample.pdf document.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the sample.pdf document.\",\\n    \"Arnauld C. Verschuur is an author associated with the sample.pdf document.\",\\n    \"Gordan M. Vujanic is an author associated with the sample.pdf document.\",\\n    \"Ivo Leuschner is an author associated with the sample.pdf document.\",\\n    \"Jesper Brok is an author associated with the sample.pdf document.\",\\n    \"Christian R\u00fcbe is an author associated with the sample.pdf document.\",\\n    \"Anne M. Smets is an author associated with the sample.pdf document.\",\\n    \"Geert O. Janssens is an author associated with the sample.pdf document.\",\\n    \"Jan Godzinski is an author associated with the sample.pdf document.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the sample.pdf document.\",\\n    \"Beatriz de Camargo is an author associated with the sample.pdf document.\",\\n    \"Heidi Segers is an author associated with the sample.pdf document.\",\\n    \"Paola Collini is an author associated with the sample.pdf document.\",\\n    \"Manfred Gessler is an author associated with the sample.pdf document.\",\\n    \"Christophe Bergeron is an author associated with the sample.pdf document.\",\\n    \"Filippo Spreafico is an author associated with the sample.pdf document.\",\\n    \"Norbert Graf is an author associated with the sample.pdf document.\",\\n    \"International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the sample.pdf document.\",\\n    \"SIOP\u2013RTSG is an organization associated with the sample.pdf document.\",\\n    \"Wilms tumour is a disease discussed in the sample.pdf document.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the sample.pdf document.\",\\n    \"Childhood renal tumours is a disease mentioned in the sample.pdf document.\",\\n    \"SIOP\u20132001 protocol is a protocol mentioned in the sample.pdf document.\",\\n    \"1q is a genomic change referenced in the sample.pdf document.\",\\n    \"www.siop-rtsg.eu is a website mentioned in the sample.pdf document.\",\\n    \"Renal tumour patients is a patient group referenced in the sample.pdf document.\",\\n    \"Consensus Statement is a document referenced in the sample.pdf document.\",\\n    \"Wilms tumours are a type of disease mentioned in the sample.pdf document.\",\\n    \"UMBRELLA protocol is another protocol mentioned in the sample.pdf document.\",\\n    \"Diagnostics is a field mentioned in the sample.pdf document.\",\\n    \"Treatment is a field mentioned in the sample.pdf document.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization mentioned in the sample.pdf document.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial discussed in the sample.pdf document.\",\\n    \"Doxorubicin is a drug mentioned in the sample.pdf document.\",\\n    \"Actinomycin D is a drug mentioned in the sample.pdf document.\",\\n    \"Vincristine is a drug mentioned in the sample.pdf document.\",\\n    \"UKW3 trial is a clinical trial mentioned in the sample.pdf document.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization mentioned in the sample.pdf document.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype referenced in the sample.pdf document.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.8, reason=\"The score is 0.80 because while the input asks specifically about the role of radiotherapy according to a specific protocol, the retrieval context mentions 'the SIOP-2001 protocol' without a clear connection. However, relevant statements highlight that 'radiotherapy is used for locoregional disease and metastatic disease management,' suggesting a significant role in the treatment protocols, thereby supporting the positive contextual relevancy.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031306499999999996, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is a protocol related to the treatment of Wilms tumours, which may involve radiotherapy.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"radiotherapy is used for locoregional disease and metastatic disease management.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"SIOP-2001 protocol is another protocol that has been followed in the past for Wilms tumour treatment, but does not specifically outline the role of radiotherapy.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement mentions the \\'SIOP-2001 protocol\\' without detailing its connection to radiotherapy.\"\\n            },\\n            {\\n                \"statement\": \"Pulmonary radiotherapy is identified as a treatment option within the protocols discussed.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"radiotherapy is a procedure that has been refined based on recent studies.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What is the role of radiotherapy according to the protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Radiotherapy is used to treat metastatic sites and in cases where a complete surgical resection is not feasible.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_11', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output does not address nephron-sparing surgery or evaluation to avoid total nephrectomy, thus failing to align with the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028399500000000004, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00836115, verbose_logs='Truths (limit=None):\\n[\\n    \"The document is titled \\'sample.pdf\\'.\",\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is mentioned.\",\\n    \"Renal tumour patients is a group.\",\\n    \"The document titled \\'Consensus Statement\\' is mentioned.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"SIOP\u22122001 is a protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"UMBRELLA protocol is a treatment protocol.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Wilms tumour is a disease.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"Lung or metastasis radiotherapy is a treatment.\",\\n    \"CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours, is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Radiotherapy is a procedure.\",\\n    \"Surgery is a procedure.\",\\n    \"Adult patients is a population.\",\\n    \"Chemotherapy is a treatment.\",\\n    \"SIOP\u2212RTSG panel is an entity.\",\\n    \"Infant Wilms tumours is a condition subcategory.\",\\n    \"Clinical guidelines is a document.\",\\n    \"Nephrectomy is a surgical procedure.\",\\n    \"Congenital mesoblastic nephroma is a condition.\",\\n    \"Malignant rhabdoid tumours is a condition.\",\\n    \"Actinomycin D is a medication.\",\\n    \"Vincristine is a medication.\",\\n    \"Anaplasia is a condition detail.\",\\n    \"Postoperative chemotherapy is a treatment phase.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a treatment regimen.\",\\n    \"Carboplatin is a medication.\",\\n    \"Cyclophosphamide is a medication.\",\\n    \"Etoposide is a medication.\",\\n    \"Doxorubicin is a medication.\",\\n    \"Surgical guidelines is a document.\",\\n    \"NSS is a surgical technique.\",\\n    \"Lymph node sampling is a surgical procedure.\",\\n    \"SIOP\u2212RTSG surgical panel is an entity.\",\\n    \"Nephron-sparing surgery (NSS) classification is a classification system.\",\\n    \"Surgery is an entity.\",\\n    \"Radiotherapy is an entity.\",\\n    \"Adult patients is an entity.\",\\n    \"Infant Wilms tumours is an entity.\",\\n    \"Nephrectomy is an entity.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is an entity.\",\\n    \"Chemotherapy is an entity.\",\\n    \"Carboplatin is an entity.\",\\n    \"Cyclophosphamide is an entity.\",\\n    \"Etoposide is an entity.\",\\n    \"Surgical guidelines is an entity.\",\\n    \"NSS is an entity.\",\\n    \"Lymph node sampling is an entity.\",\\n    \"Nephron-sparing surgery (NSS) classification is an entity.\",\\n    \"Minimally invasive surgery is a procedure.\",\\n    \"Laparoscopic surgery is a procedure.\",\\n    \"NSS is a procedure.\",\\n    \"Radiotherapy is a treatment.\",\\n    \"Wilms tumours is a condition.\",\\n    \"SIOP\u22122001 is a study.\",\\n    \"COG\u2013NWTS trials is a study.\",\\n    \"Proton therapy is a treatment.\",\\n    \"Locoregional disease is a condition.\",\\n    \"Metastatic disease is a condition.\",\\n    \"Low-risk is a risk level.\",\\n    \"Intermediate-risk is a risk level.\",\\n    \"High-risk is a risk level.\",\\n    \"High-risk blastemal-type Wilms tumour is a condition.\",\\n    \"High-risk diffuse anaplasia is a condition.\",\\n    \"Iceland is a country.\",\\n    \"UMBRELLA protocol is a protocol.\",\\n    \"SIOP renal tumour protocol is a protocol.\",\\n    \"Europe is a region.\",\\n    \"European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization.\",\\n    \"ExPO-r-Net is a project.\",\\n    \"Germany is a country.\",\\n    \"Italy is a country.\",\\n    \"Netherlands is a country.\",\\n    \"Poland is a country.\",\\n    \"Austria is a country.\",\\n    \"France is a country.\",\\n    \"Spain is a country.\",\\n    \"UK is a country.\",\\n    \"COG is an organization.\",\\n    \"Europe is an entity.\",\\n    \"International collaboration is an entity.\",\\n    \"Iceland is an entity.\",\\n    \"Weirich, A. is an author.\",\\n    \"Children\u2019s Oncology Group study AREN0533 is a study.\",\\n    \"SIOP-9/GPOH is a trial.\",\\n    \"Terenziani, M. is an author.\",\\n    \"Adult Wilms\u2019 tumor is a condition.\",\\n    \"Daw, N. C. is an author.\",\\n    \"Vincristine and irinotecan is a treatment.\",\\n    \"Children\u2019s Oncology Group AREN0321 is a study.\",\\n    \"Ha, T. C. is an author.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is a treatment.\",\\n    \"Kremens, B. is an author.\",\\n    \"Autologous stem cell rescue is a treatment.\",\\n    \"Furtwangler, R. is an author.\",\\n    \"GPOH-nephroblastoma study group is a group.\",\\n    \"SIOP Renal Tumour Study Group (SIOP-RTSG) is a group.\",\\n    \"SIOP WT 2001 is a protocol.\",\\n    \"D\u2019Angio, G. J. is an author.\",\\n    \"National Wilms\u2019 Tumor Study is a study.\",\\n    \"SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is associated with the UMBRELLA SIOP\u2013RTSG 2016 protocol.\",\\n    \"Renal tumour patients is a group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"The EFS (event-free survival) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"The SIOP database is a database.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The Children\u2019s Oncology Group study AREN0533 is a study.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Liver or metastasis radiotherapy is a treatment.\",\\n    \"The surgical guidelines is a document.\",\\n    \"The SIOP\u2013RTSG surgical panel is an entity.\",\\n    \"The SIOP Pathology Panel is a panel.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.4, reason=\"The score is 0.40 because while there are relevant statements such as 'The UMBRELLA SIOP\u2013RTSG 2016 protocol addresses treatment for Bilateral Wilms tumours' and 'The UMBRELLA protocol provides guidelines for surgical treatment options including nephron-sparing surgery,' the retrieval context also contained significant irrelevant information, like 'Bilateral Wilms tumour can cause ESRD,' which detracted from the overall relevance to the input.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031539, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"Bilateral Wilms tumour can cause ESRD.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context contained the information \\'Bilateral Wilms tumour can cause ESRD\\' which is not about addressing bilateral renal tumours in the protocol.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol addresses treatment for Bilateral Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumours are part of a larger category of childhood renal tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context contained the information \\'Wilms tumours are part of a larger category of childhood renal tumours\\' which is not directly addressing bilateral renal tumours.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol provides guidelines for surgical treatment options including nephron-sparing surgery.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Current studies explore new treatments for high-risk renal tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context contained the information \\'Current studies explore new treatments for high-risk renal tumours\\' which does not specifically address bilateral renal tumours.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How are bilateral renal tumours addressed in the protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Bilateral tumours are managed with a focus on nephron-sparing surgery and careful evaluation to avoid total nephrectomy.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_12', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output contains no information regarding the reduction of whole-lung irradiation dose as mentioned in the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028363499999999996, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=False, score=0.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0083136, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group (SIOP\u2013RTSG) is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a type of genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to SIOP\u2013RTSG.\",\\n    \"The renal tumour patients group consists of patients diagnosed with renal tumours.\",\\n    \"A Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\",\\n    \"Diagnostics is a field of study.\",\\n    \"Treatment is a field of study.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"The EFS probability is a metric.\",\\n    \"The OS probability is a metric.\",\\n    \"The 60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"The 60-month OS \u2013 <500 ml is an outcome.\",\\n    \"The 60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"The 60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013rank P is a statistic.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"The COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment regimen.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The SIOP\u22122001 protocol relates to treatment protocols.\",\\n    \"The AREN0533 study is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The SIOP database captures outcomes of treatments.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 and AVD250 are treatment entities.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"High-risk diffuse anaplasia is a condition.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Iceland, Germany, Italy, Netherlands, Poland, Austria, France, Spain, and UK are countries involved in the study.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is an organization.\",\\n    \"The National Wilms\u2019 Tumor Study is a study.\",\\n    \"D\u2019Angio, G. J. is an author.\",\\n    \"SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr. Ivo Leuschner is a person.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author associated with the document titled \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document titled \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document titled \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours is a disease mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"SIOP\u20132001 protocol is a protocol mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"1q is a genomic change mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"The website www.siop-rtsg.eu is referenced in the document titled \\'sample.pdf\\'.\",\\n    \"Renal tumour patients are a group referenced in the document titled \\'sample.pdf\\'.\",\\n    \"A Consensus Statement is a document referenced in the document titled \\'sample.pdf\\'.\",\\n    \"Wilms tumours is a disease mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"Diagnostics is a field referenced in the document titled \\'sample.pdf\\'.\",\\n    \"Treatment is a field referenced in the document titled \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization associated with the document titled \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a drug mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a drug mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"Vincristine is a drug mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"The UKW3 trial is a clinical trial mentioned in the document titled \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization associated with the document titled \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document titled \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Marry M. van den Heuvel-Eibrink is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Janna A. Hol is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Kathy Pritchard-Jones is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Harm van Tinteren is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Rhoikos Furtw\\\\u00e4ngler is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Arnauld C. Verschuur is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Gordan M. Vujanic is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Ivo Leuschner is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Jesper Brok is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Christian R\\\\u00fcbe is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Anne M. Smets is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Geert O. Janssens is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Jan Godzinski is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Gema L. Ram\\\\u00edrez-Villar is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Beatriz de Camargo is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Heidi Segers is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Paola Collini is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Manfred Gessler is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Christophe Bergeron is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Filippo Spreafico is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Norbert Graf is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming SIOP\\\\u2013RTSG is associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Wilms tumour is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Childhood renal tumours is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming SIOP\\\\u20132001 protocol is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming 1q is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming the website www.siop-rtsg.eu is referenced in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming renal tumour patients as a group referenced in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming A Consensus Statement is referenced in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Wilms tumours as a disease mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The UMBRELLA protocol is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Diagnostics as a field referenced in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Treatment as a field referenced in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The Children\\\\u2019s Oncology Group (COG) as an organization associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The SIOP\\\\u22122001 randomized trial is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Doxorubicin is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Actinomycin D is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming Vincristine is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The UKW3 trial is mentioned in the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming The UK Children\\\\u2019s Cancer and Leukaemia Group (UKCCLG) as an organization associated with the document titled \\'sample.pdf\\'.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"There is no information confirming High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document titled \\'sample.pdf\\'.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.4, reason=\"The score is 0.40 because the provided context largely discusses unrelated topics, such as chemotherapy protocols and detection rather than specifics about radiotherapy dosage for lung metastases. Relevant statements like 'pulmonary radiotherapy is a treatment for Wilms tumour' and 'no radiotherapy to metastases is a treatment protocol recommendation' offer some connection, but they do not directly address the question about radiotherapy dosage.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031264500000000002, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"pulmonary radiotherapy is a treatment for Wilms tumour\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol includes treatment for CCSK, MRTK, CMN, RCC.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The mention of \\'CCSK, MRTK, CMN, RCC\\' does not directly address radiotherapy dosage for lung metastases.\"\\n            },\\n            {\\n                \"statement\": \"chest CT detects pulmonary nodules.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The focus is on detection and not on treatment or dosage specifics related to lung metastases.\"\\n            },\\n            {\\n                \"statement\": \"high-dose chemotherapy and autologous stem cell transplantation is included in the SIOP-2001 protocol.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This information is about chemotherapy protocols and does not pertain to radiotherapy dosage.\"\\n            },\\n            {\\n                \"statement\": \"no radiotherapy to metastases is a treatment protocol recommendation.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What does the protocol suggest about radiotherapy dosage for lung metastases?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='It suggests that the whole-lung irradiation dose may be reduced (for example, from 15 Gy to 12 Gy) in selected cases.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_9', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason=\"The actual output does not address the criteria regarding preoperative chemotherapy's purpose, instead providing an unrelated list of entities and documents.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00283665, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=False, score=0.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.008147999999999999, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a clinical protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is mentioned.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a clinical protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u22122001 randomized control trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment regimen.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The SIOP database is a database.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Stage IV WT is a disease stage.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author associated with the document \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease referenced in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours is a disease referenced in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u20132001 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"1q is a genomic change referenced in the document \\'sample.pdf\\'.\",\\n    \"The website www.siop-rtsg.eu is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients is a patient group referenced in the document \\'sample.pdf\\'.\",\\n    \"The Consensus Statement is a document referenced in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumours is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Diagnostics is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Treatment is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial referenced in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UKW3 trial is a clinical trial referenced in the document \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization referenced in the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Marry M. van den Heuvel-Eibrink is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Janna A. Hol is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Kathy Pritchard-Jones is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Harm van Tinteren is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Rhoikos Furtw\\\\u00e4ngler is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Arnauld C. Verschuur is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gordan M. Vujanic is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Ivo Leuschner is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jesper Brok is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christian R\\\\u00fcbe is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Anne M. Smets is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Geert O. Janssens is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jan Godzinski is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gema L. Ram\\\\u00edrez-Villar is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Beatriz de Camargo is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Heidi Segers is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Paola Collini is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Manfred Gessler is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christophe Bergeron is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Filippo Spreafico is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Norbert Graf is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP\\\\u2013RTSG is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumour is referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Childhood renal tumours is referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The SIOP\\\\u20132001 protocol is mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 1q is a genomic change referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The website www.siop-rtsg.eu is mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Renal tumour patients is a patient group referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The Consensus Statement is a document referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumours is mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The UMBRELLA protocol is mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Diagnostics is a field mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Treatment is a field mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The Children\\\\u2019s Oncology Group (COG) is associated with the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The SIOP\\\\u22122001 randomized trial is a clinical trial referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Doxorubicin is a drug mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Actinomycin D is a drug mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Vincristine is a drug mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The UKW3 trial is a clinical trial referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states The UK Children\\\\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization referenced in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document \\'sample.pdf\\', but the retrieval context does not provide any information about document associations.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.0, reason='The score is 0.00 because there are no relevant statements in the retrieval context that address the significance of preoperative chemotherapy, making it entirely irrelevant to the input.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0033433499999999997, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"SIOP\\\\u20132001 randomized trial evaluates postoperative chemotherapy.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context contained the information \\'evaluates postoperative chemotherapy\\', which does not specifically pertain to the significance of preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"Postoperative chemotherapy is included in protocols for various Wilms tumour treatments.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context mentions \\'postoperative chemotherapy\\', which is not relevant to the input asking about preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"High dose therapy can be a treatment option in recurrent Wilms\\\\u2019 tumour.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context discusses \\'high dose therapy\\', which does not relate to the significance of preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP-RTSG 2016 protocol includes various treatments for Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context refers to \\'treatment for Wilms tumours\\', which is not directly related to preoperative chemotherapy or its significance.\"\\n            },\\n            {\\n                \"statement\": \"Clinical trials have tested vincristine and actinomycin D for different stages of Wilms tumour.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement regarding \\'vincristine and actinomycin D\\' focuses on treatments rather than addressing the impact of preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"No evidence of metastasis is found in children treated for Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement relates to diagnostic outcomes, which does not provide insight into the importance of preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"Chemotherapy-resistant diseases often require intensive follow-up treatments.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement discusses \\'chemotherapy-resistant diseases\\', which is irrelevant to the preoperative context.\"\\n            },\\n            {\\n                \"statement\": \"Recommendations for radiotherapy in locoregional Wilms tumour management.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context emphasizes \\'radiotherapy\\', which is outside the focus on preoperative chemotherapy significance.\"\\n            },\\n            {\\n                \"statement\": \"Use of chest CT is crucial for detecting complications in treated patients.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement is geared toward diagnostic imaging rather than preoperative chemotherapy\\'s role.\"\\n            },\\n            {\\n                \"statement\": \"Surgical guidelines suggest nephron-sparing techniques for certain Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The reference to \\'surgical guidelines\\' does not connect to the inquiry about preoperative chemotherapy.\"\\n            },\\n            {\\n                \"statement\": \"Long-term survival rates can be affected by the type of chemotherapy administered.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While related to chemotherapy, it does not specifically discuss the importance of preoperative chemotherapy.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What is the significance of preoperative chemotherapy in the protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Preoperative chemotherapy is used to downstage the tumor and assess its chemosensitivity before surgery.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_15', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.006082631200875889, reason='The actual output does not address the comprehensive and wide-ranging approach to treating paediatric renal tumours as stated in the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028369499999999995, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.008496299999999998, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours are a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is related to the SIOP\u2013RTSG.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours are a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours are a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"The Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours are a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules are a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"Large-volume tumours are associated with event-free survival (EFS).\",\\n    \"Metastatic disease is associated with stage IV disease.\",\\n    \"The UMBRELLA protocol includes guidelines for surgery.\",\\n    \"Wilms tumours guide treatment.\",\\n    \"The UMBRELLA protocol is defined in terms of treatment for Group AA, Group BB, and Group CC.\",\\n    \"The UMBRELLA protocol includes diagnostic tests.\",\\n    \"The UMBRELLA protocol includes the SIOP\u2212RTSG panel.\",\\n    \"The UMBRELLA protocol emphasizes the importance of lymph node sampling.\",\\n    \"The UMBRELLA protocol adopts nephron-sparing surgery (NSS) classification.\",\\n    \"Wilms tumours have an associated risk level classified as low-risk, intermediate-risk, and high-risk.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP-RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is associated with SIOP-RTSG.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u20132001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Vincristine is a chemical.\",\\n    \"Actinomycin D is a chemical.\",\\n    \"Doxorubicin is a chemical.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"The SIOP\u22122001 protocol is a treatment protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"The SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Wilms tumour is a disease.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"The confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"Lung or metastasis radiotherapy is a treatment.\",\\n    \"CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"The Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Stage IV WT is an entity.\",\\n    \"Low-risk disease is an entity.\",\\n    \"Intermediate-risk disease is an entity.\",\\n    \"High-risk disease is an entity.\",\\n    \"The confirm metastatic disease by histology is an entity.\",\\n    \"Liver or metastasis radiotherapy is an entity.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"SIOP\u2013RTSG has published the UMBRELLA-SIOP-RTSG-2016 protocol.\",\\n    \"SIOP\u2013RTSG has developed the UMBRELLA protocol.\",\\n    \"Surgery is addressed in the UMBRELLA protocol.\",\\n    \"Radiotherapy was refined based on the SIOP\u22122001.\",\\n    \"Radiotherapy was refined based on the COG\u2013NWTS trials.\",\\n    \"Radiotherapy is used for locoregional disease.\",\\n    \"Radiotherapy is used for metastatic disease.\",\\n    \"Infant Wilms tumours are considered for primary surgery in nephrectomy.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a type of chemotherapy.\",\\n    \"Carboplatin is used in chemotherapy.\",\\n    \"Cyclophosphamide is used in chemotherapy.\",\\n    \"Etoposide is used in chemotherapy.\",\\n    \"Nephron-sparing surgery (NSS) is acceptable for treatment of Wilms tumour.\",\\n    \"Nephron-sparing surgery (NSS) is subject to nephron-sparing surgery (NSS) classification.\",\\n    \"Proton therapy needs investigation before implementation in UMBRELLA protocol.\",\\n    \"Iceland is part of an international collaboration.\",\\n    \"The SIOP renal tumour protocol is a protocol.\",\\n    \"Europe is a region.\",\\n    \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization.\",\\n    \"ExPO-r-Net is a project.\",\\n    \"Germany is a country.\",\\n    \"University Hospital of Munich is located in Germany.\",\\n    \"Italy is a country.\",\\n    \"Azienda Ospedaliera, Padova is located in Italy.\",\\n    \"The Netherlands is a country.\",\\n    \"Prinses Maxima Centrum, Utrecht is located in the Netherlands.\",\\n    \"Poland is a country.\",\\n    \"Marciniak Hospital, Wroclaw is located in Poland.\",\\n    \"Austria is a country.\",\\n    \"St. Anna Kinderspital/CCRI, Vienna is located in Austria.\",\\n    \"France is a country.\",\\n    \"Armand Trousseau Hospital, Paris is located in France.\",\\n    \"Spain is a country.\",\\n    \"Hospital Universitario Virgin del Rocio, Seville is located in Spain.\",\\n    \"The UK is a country.\",\\n    \"Great Ormond Street Hospital, London is located in the UK.\",\\n    \"Weirich, A. participated in SIOP-9/GPOH study.\",\\n    \"Weirich, A. participated in the Children\u2019s Oncology Group study AREN0533.\",\\n    \"Terenziani, M. researched Adult Wilms\u2019 tumor.\",\\n    \"Daw, N. C. studied vincristine and irinotecan treatment.\",\\n    \"Daw, N. C. participated in Children\u2019s Oncology Group AREN0321.\",\\n    \"Ha, T. C. proposed high dose therapy in recurrent Wilms\u2019 tumour.\",\\n    \"Kremens, B. researched autologous stem cell rescue.\",\\n    \"Furtwangler, R. is a member of GPOH-nephroblastoma study group.\",\\n    \"SIOP Renal Tumour Study Group (SIOP-RTSG) developed SIOP WT 2001.\",\\n    \"D\u2019Angio, G. J. contributed to National Wilms\u2019 Tumor Study.\",\\n    \"Prof. Dr Ivo Leuschner is a co-chair and member of SIOP Pathology Panel.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.875, reason=\"The score is 0.88 because while the mention of the 'UMBRELLA SIOP\u2013RTSG 2016 protocol' provides some context relevant to the term 'UMBRELLA', the predominant focus on the 'Children's Oncology Group study' diverts from its symbolic meaning. Thus, the connection is significant but not perfect.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031716, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA SIOP-RTSG 2016 protocol_ENTITY\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol_I_entity\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol_entity\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol_treatment_protocol\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol_entity\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA-Children\\'s Oncology Group study\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement contains \\'Children\\'s Oncology Group study\\' which doesn\\'t directly relate to the symbolism of the term \\'UMBRELLA\\' but rather to a context of studies.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What does the term \u2018UMBRELLA\u2019 symbolize in this context?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='It symbolizes the comprehensive and wide-ranging approach to treating all paediatric renal tumours.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_16', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.017346458623067693, reason='The actual output does not recommend direct surgery or biopsy in atypical cases, failing to address the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00283515, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.008384550000000001, verbose_logs='Truths (limit=None):\\n[\\n    \"The document is titled \\'sample.pdf\\'.\",\\n    \"Marry M. van den Heuvel-Eibrink is one of the authors.\",\\n    \"Janna A. Hol is one of the authors.\",\\n    \"Kathy Pritchard-Jones is one of the authors.\",\\n    \"Harm van Tinteren is one of the authors.\",\\n    \"Rhoikos Furtw\u00e4ngler is one of the authors.\",\\n    \"Arnauld C. Verschuur is one of the authors.\",\\n    \"Gordan M. Vujanic is one of the authors.\",\\n    \"Ivo Leuschner is one of the authors.\",\\n    \"Jesper Brok is one of the authors.\",\\n    \"Christian R\u00fcbe is one of the authors.\",\\n    \"Anne M. Smets is one of the authors.\",\\n    \"Geert O. Janssens is one of the authors.\",\\n    \"Jan Godzinski is one of the authors.\",\\n    \"Gema L. Ram\u00edrez-Villar is one of the authors.\",\\n    \"Beatriz de Camargo is one of the authors.\",\\n    \"Heidi Segers is one of the authors.\",\\n    \"Paola Collini is one of the authors.\",\\n    \"Manfred Gessler is one of the authors.\",\\n    \"Christophe Bergeron is one of the authors.\",\\n    \"Filippo Spreafico is one of the authors.\",\\n    \"Norbert Graf is one of the authors.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is mentioned in the document.\",\\n    \"Renal tumour patients is a group.\",\\n    \"There is a Consensus Statement document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics and treatment are fields mentioned.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a Clinical Trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"The EFS probability is a metric.\",\\n    \"The OS probability is a metric.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author of the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author of the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author of the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author of the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author of the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author of the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author of the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author of the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author of the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author of the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author of the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author of the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author of the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author of the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author of the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author of the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author of the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author of the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author of the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author of the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author of the document \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization related to the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization related to the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours are mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP\u20132001 protocol is mentioned in the document \\'sample.pdf\\'.\",\\n    \"1q is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The website www.siop-rtsg.eu is associated with the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Consensus Statement is a document referenced in the sample.pdf.\",\\n    \"Wilms tumours are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Diagnostics is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Treatment is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization related to the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u20132001 randomized trial is a clinical trial referenced in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UKW3 trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization related to the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours are mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study referenced in the document \\'sample.pdf\\'.\",\\n    \"CT-only nodules are a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The COG protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"The NWTS-4 study is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"The NWTS-5 study is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment regimen mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP database is a database referenced in the document \\'sample.pdf\\'.\",\\n    \"Bilateral Wilms tumour is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"ESRD is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"WAGR syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Denys-Drash syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a treatment protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group AA is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group BB is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group CC is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage IV WT is a disease stage mentioned in the document \\'sample.pdf\\'.\",\\n    \"Low-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Intermediate-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules >5mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Other site is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Viable metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Completely necrotic metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastasis confirmed is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Confirm metastatic disease by histology is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD150 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD250 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"CT at week 10 is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"No radiotherapy to metastases is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Four-drug regimen is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"CDCV is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Initial diffuse anaplasia is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Blastemal-type tumours is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No response to salvage treatment is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Camptothecins is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Irinotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Topotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Novel compounds is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chemotherapy-resistant disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u2212RTSG is an organization related to the document \\'sample.pdf\\'.\",\\n    \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization related to the document \\'sample.pdf\\'.\",\\n    \"Iceland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Germany is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Italy is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Netherlands is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Poland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Austria is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"France is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Spain is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"ExPO-r-Net is a project mentioned in the document \\'sample.pdf\\'.\",\\n    \"The involvement of countries such as Iceland, Germany, Italy, the Netherlands, Poland, Austria, France, Spain, and the UK is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The study by the Children\u2019s Oncology Group AREN0533 is referenced in the document \\'sample.pdf\\'.\",\\n    \"The organization GPOH-nephroblastoma study group is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Daw, N. C. is an author mentioned in relation to \\'Daw, N. C.\\'s involvement in studying vincristine and irinotecan in the document \\'sample.pdf\\'.\",\\n    \"Terenziani, M. is an author related to Adult Wilms\u2019 tumor and is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Ha, T. C. is an author who proposed a high dose therapy in recurrent Wilms\u2019 tumor and is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Kremens, B. is an author related to autologous stem cell rescue and is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Weirich, A. is an author who participated in various studies related to the document \\'sample.pdf\\'.\",\\n    \"Furtwangler, R. is an author who is a member of the GPOH-nephroblastoma study group and is mentioned in the document \\'sample.pdf\\'.\",\\n    \"D\u2019Angio, G. J. is an author who contributed to the National Wilms\u2019 Tumor Study and is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Prof. Dr Ivo Leuschner is an author mentioned alongside the SIOP Pathology Panel in the document \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.0, reason='The score is 0.00 because there is no relevant information in the context regarding how the protocol handles cases of misdiagnosis; all reasons for irrelevance highlight a lack of specific actions or strategies related to misdiagnosis.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0031084499999999996, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol proposes handling cases of misdiagnosis.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context does not provide specific strategies or actions regarding how misdiagnosis is handled, but rather mentions the protocol in general without elaboration.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA SIOP\\\\u2013RTSG protocol is involved with renal tumour patients.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"While it references patients, it does not directly relate to handling misdiagnosis.\"\\n            },\\n            {\\n                \"statement\": \"Wilms tumours are affected by diagnostic protocols.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement is too vague and does not specifically mention misdiagnosis handling.\"\\n            },\\n            {\\n                \"statement\": \"The International Society of Paediatric Oncology - Renal Tumour Study Group works with treatment protocols.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This is about treatment protocols rather than addressing misdiagnosis.\"\\n            },\\n            {\\n                \"statement\": \"Wilms tumours require various treatment approaches.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This is relevant to treatment rather than the handling of misdiagnosis.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How does the protocol propose handling cases of misdiagnosis?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='It recommends direct surgery or biopsy in cases where imaging and clinical features are atypical to avoid treatment delays.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_18', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.013583549852484786, reason='The actual output lacks any reference to the protocol being implemented in over 50 countries, as stated in the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028363499999999996, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00849975, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is one of the authors of the document.\",\\n    \"Janna A. Hol is one of the authors of the document.\",\\n    \"Kathy Pritchard-Jones is one of the authors of the document.\",\\n    \"Harm van Tinteren is one of the authors of the document.\",\\n    \"Rhoikos Furtw\u00e4ngler is one of the authors of the document.\",\\n    \"Arnauld C. Verschuur is one of the authors of the document.\",\\n    \"Gordan M. Vujanic is one of the authors of the document.\",\\n    \"Ivo Leuschner is one of the authors of the document.\",\\n    \"Jesper Brok is one of the authors of the document.\",\\n    \"Christian R\u00fcbe is one of the authors of the document.\",\\n    \"Anne M. Smets is one of the authors of the document.\",\\n    \"Geert O. Janssens is one of the authors of the document.\",\\n    \"Jan Godzinski is one of the authors of the document.\",\\n    \"Gema L. Ram\u00edrez-Villar is one of the authors of the document.\",\\n    \"Beatriz de Camargo is one of the authors of the document.\",\\n    \"Heidi Segers is one of the authors of the document.\",\\n    \"Paola Collini is one of the authors of the document.\",\\n    \"Manfred Gessler is one of the authors of the document.\",\\n    \"Christophe Bergeron is one of the authors of the document.\",\\n    \"Filippo Spreafico is one of the authors of the document.\",\\n    \"Norbert Graf is one of the authors of the document.\",\\n    \"The International Society of Paediatric Oncology - Renal Tumour Study Group is an organization involved in the context of the document.\",\\n    \"SIOP-RTSG is an organization involved in the context of the document.\",\\n    \"Wilms tumour is a type of disease mentioned in the document.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol referenced in the document.\",\\n    \"Childhood renal tumours is a disease mentioned in the document.\",\\n    \"The SIOP\u20132001 protocol is a protocol referenced in the document.\",\\n    \"1q is a genomic change mentioned in the document.\",\\n    \"The website www.siop-rtsg.eu is mentioned in the document.\",\\n    \"Renal tumour patients are a group referenced in the document.\",\\n    \"A Consensus Statement is mentioned as a document in the context.\",\\n    \"Wilms tumours is a disease mentioned in the document.\",\\n    \"The UMBRELLA protocol is a protocol referenced in the document.\",\\n    \"Diagnostics is a field mentioned in relation to the context of the document.\",\\n    \"Treatment is a field mentioned in relation to the context of the document.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization mentioned in the document.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial referenced in the document.\",\\n    \"Doxorubicin is a drug mentioned in the document.\",\\n    \"Actinomycin D is a drug mentioned in the document.\",\\n    \"Vincristine is a drug mentioned in the document.\",\\n    \"The UKW3 trial is a clinical trial referenced in the document.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization mentioned in the document.\",\\n    \"High-risk, blastemal-type Wilms tumours is a subtype of disease mentioned in the document.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours are diseases.\",\\n    \"The SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu contains relevant information.\",\\n    \"Renal tumour patients form a group.\",\\n    \"The Consensus Statement is a document.\",\\n    \"Wilms tumours are diseases.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field related to medical assessment.\",\\n    \"Treatment is a field related to medical care.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"The UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours are a disease subtype.\",\\n    \"Vincristine is a chemical.\",\\n    \"Actinomycin D is a chemical.\",\\n    \"Doxorubicin is a chemical.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"The SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours are a medical condition.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules are a medical condition.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"Event-free survival (EFS) is an entity.\",\\n    \"Large-volume tumours are an entity.\",\\n    \"Stage II\u2013III regressive, mixed, and focal anaplasia-type tumours are an entity.\",\\n    \"Metastatic disease is an entity.\",\\n    \"Stage IV disease is an entity.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules are a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"SIOP\u22122001 is a protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"The UMBRELLA protocol is a treatment protocol.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Wilms tumour is a disease.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm are a disease characteristic.\",\\n    \"Lung nodules >5mm are a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"Lung or metastasis radiotherapy is a treatment.\",\\n    \"CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours are a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"The Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Stage IV WT is an entity.\",\\n    \"Low-risk disease is an entity.\",\\n    \"Intermediate-risk disease is an entity.\",\\n    \"High-risk disease is an entity.\",\\n    \"Confirm metastatic disease by histology is an entity.\",\\n    \"Liver or metastasis radiotherapy is an entity.\",\\n    \"AVD150 is an entity.\",\\n    \"AVD250 is an entity.\",\\n    \"Pulmonary radiotherapy is an entity.\",\\n    \"Four-drug regimen is an entity.\",\\n    \"SIOP\u2013RTSG is an entity.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is an entity.\",\\n    \"Radiotherapy is a procedure.\",\\n    \"Surgery is a procedure.\",\\n    \"Wilms tumour is a condition.\",\\n    \"Adult patients are a population.\",\\n    \"Chemotherapy is a treatment.\",\\n    \"The SIOP\u2212RTSG panel is an entity.\",\\n    \"Infant Wilms tumours are a condition subcategory.\",\\n    \"The clinical guidelines is a document.\",\\n    \"Nephrectomy is a surgical procedure.\",\\n    \"Congenital mesoblastic nephroma is a condition.\",\\n    \"Malignant rhabdoid tumours are a condition.\",\\n    \"Actinomycin D is a medication.\",\\n    \"Vincristine is a medication.\",\\n    \"Anaplasia is a condition detail.\",\\n    \"Postoperative chemotherapy is a treatment phase.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a treatment regimen.\",\\n    \"Carboplatin is a medication.\",\\n    \"Cyclophosphamide is a medication.\",\\n    \"Etoposide is a medication.\",\\n    \"Doxorubicin is a medication.\",\\n    \"The surgical guidelines is a document.\",\\n    \"NSS is a surgical technique.\",\\n    \"Lymph node sampling is a surgical procedure.\",\\n    \"The SIOP\u2212RTSG surgical panel is an entity.\",\\n    \"The nephron-sparing surgery (NSS) classification is a classification system.\",\\n    \"Surgery is an entity.\",\\n    \"Radiotherapy is an entity.\",\\n    \"Adult patients are an entity.\",\\n    \"Infant Wilms tumours are an entity.\",\\n    \"Nephrectomy is an entity.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is an entity.\",\\n    \"Chemotherapy is an entity.\",\\n    \"Carboplatin is an entity.\",\\n    \"Cyclophosphamide is an entity.\",\\n    \"Etoposide is an entity.\",\\n    \"The surgical guidelines is an entity.\",\\n    \"NSS is an entity.\",\\n    \"Lymph node sampling is an entity.\",\\n    \"The nephron-sparing surgery (NSS) classification is an entity.\",\\n    \"Minimally invasive surgery is a procedure.\",\\n    \"Laparoscopic surgery is a procedure.\",\\n    \"NSS is a procedure.\",\\n    \"Radiotherapy is a treatment.\",\\n    \"Wilms tumours are a condition.\",\\n    \"The SIOP\u22122001 is a study.\",\\n    \"The COG\u2013NWTS trials is a study.\",\\n    \"Proton therapy is a treatment.\",\\n    \"Locoregional disease is a condition.\",\\n    \"Metastatic disease is a condition.\",\\n    \"Low-risk is a risk level.\",\\n    \"Intermediate-risk is a risk level.\",\\n    \"High-risk is a risk level.\",\\n    \"High-risk blastemal-type Wilms tumour is a condition.\",\\n    \"High-risk diffuse anaplasia is a condition.\",\\n    \"The COG\u2013NWTS trials is an entity.\",\\n    \"Proton therapy is an entity.\",\\n    \"Locoregional disease is an entity.\",\\n    \"Iceland is a country.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"The SIOP renal tumour protocol is a protocol.\",\\n    \"Europe is a region.\",\\n    \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization.\",\\n    \"ExPO-r-Net is a project.\",\\n    \"Germany is a country.\",\\n    \"Italy is a country.\",\\n    \"The Netherlands is a country.\",\\n    \"Poland is a country.\",\\n    \"Austria is a country.\",\\n    \"France is a country.\",\\n    \"Spain is a country.\",\\n    \"The UK is a country.\",\\n    \"COG is an organization.\",\\n    \"Europe is an entity.\",\\n    \"International collaboration is an entity.\",\\n    \"Iceland is an entity.\",\\n    \"Weirich, A. is an author.\",\\n    \"The Children\\'s Oncology Group study AREN0533 is a study.\",\\n    \"The SIOP-9/GPOH trial is a trial.\",\\n    \"Terenziani, M. is an author.\",\\n    \"Adult Wilms\u2019 tumor is a condition.\",\\n    \"Daw, N. C. is an author.\",\\n    \"Vincristine and irinotecan is a treatment.\",\\n    \"The Children\u2019s Oncology Group AREN0321 is a study.\",\\n    \"Ha, T. C. is an author.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is a treatment.\",\\n    \"Kremens, B. is an author.\",\\n    \"Autologous stem cell rescue is a treatment.\",\\n    \"Furtwangler, R. is an author.\",\\n    \"GPOH-nephroblastoma study group is a group.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is a group.\",\\n    \"The SIOP WT 2001 is a protocol.\",\\n    \"D\u2019Angio, G. J. is an author.\",\\n    \"The National Wilms\u2019 Tumor Study is a study.\",\\n    \"The SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.6, reason=\"The score is 0.60 because while there are relevant statements like 'UMBRELLA protocol facilitates international collaboration' that directly address the input, other statements about 'regional collaboration' and 'COG studies' detract from its relevance to international collaboration.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0030877499999999998, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA protocol facilitates international collaboration.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Iceland is part of international collaboration.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Children\\\\u2019s Oncology Group (COG) studies are significant in pediatric oncology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement about \\'Children\\\\u2019s Oncology Group (COG) studies\\' does not directly address the emphasis on \\'international collaboration\\' in the protocol.\"\\n            },\\n            {\\n                \"statement\": \"The SIOP Renal Tumour Study Group develops protocols that are applied internationally.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment promotes regional collaboration.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement specifically mentions \\'regional collaboration,\\' which is not the same as \\'international collaboration.\\'\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How is international collaboration emphasized in the protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='The protocol is designed to be implemented in over 50 countries, facilitating data sharing and research across borders.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_3', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output does not contain the expected output text; it lists entities and relationships, missing the integration statement.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028337999999999996, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=False, score=0.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00858315, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"The website www.siop-rtsg.eu is available.\",\\n    \"Renal tumour patients is a patient group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a subtype of disease.\",\\n    \"Vincristine is a chemical.\",\\n    \"Actinomycin D is a chemical.\",\\n    \"Doxorubicin is a chemical.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours is a medical condition.\",\\n    \"Stromal tumour types is a medical condition.\",\\n    \"Epithelial tumour types is a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours is a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules is a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"SIOP\u22122001 is a protocol.\",\\n    \"AREN0533 is a study.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"UMBRELLA protocol is a treatment protocol.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Wilms tumour is a disease.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"Lung or metastasis radiotherapy is a treatment.\",\\n    \"CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Relapsed group CC is a patient group.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"Blastemal-type tumours is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"Chemotherapy-resistant disease is a condition.\",\\n    \"UMBRELLA-SIOP-RTSG-2016 protocol is a protocol.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Stage IV WT is a disease entity.\",\\n    \"Low-risk disease is a disease entity.\",\\n    \"Intermediate-risk disease is a disease entity.\",\\n    \"High-risk disease is a disease entity.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"Liver or metastasis radiotherapy is a treatment.\",\\n    \"AVD150 is a treatment for Wilms tumour.\",\\n    \"AVD250 is a treatment for Wilms tumour.\",\\n    \"Pulmonary radiotherapy is a treatment for Wilms tumour.\",\\n    \"Four-drug regimen is a treatment for high-risk disease.\",\\n    \"SIOP\u2013RTSG publishes UMBRELLA-SIOP-RTSG-2016 protocol.\",\\n    \"SIOP\u2013RTSG developed UMBRELLA protocol.\",\\n    \"Surgery is addressed in UMBRELLA protocol.\",\\n    \"Radiotherapy was refined based on SIOP\u22122001.\",\\n    \"Radiotherapy was refined based on COG\u2013NWTS trials.\",\\n    \"Radiotherapy is used for locoregional disease.\",\\n    \"Radiotherapy is used for metastatic disease.\",\\n    \"Infant Wilms tumours are considered for primary surgery with nephrectomy.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a type of chemotherapy.\",\\n    \"Carboplatin is used in chemotherapy.\",\\n    \"Cyclophosphamide is used in chemotherapy.\",\\n    \"Etoposide is used in chemotherapy.\",\\n    \"NSS is acceptable for treatment of Wilms tumour.\",\\n    \"NSS is subject to nephron-sparing surgery (NSS) classification.\",\\n    \"Proton therapy needs investigation before implementation in UMBRELLA protocol.\",\\n    \"Iceland is part of international collaboration.\",\\n    \"SIOP-9/GPOH is a trial.\",\\n    \"Children\\'s Oncology Group study AREN0533 is a study.\",\\n    \"Adult Wilms\u2019 tumor is a condition.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is treatment.\",\\n    \"Autologous stem cell rescue is treatment for high-risk patients.\",\\n    \"GPOH-nephroblastoma study group is a group.\",\\n    \"SIOP Renal Tumour Study Group (SIOP-RTSG) developed SIOP WT 2001.\",\\n    \"D\u2019Angio, G. J. contributed to National Wilms\u2019 Tumor Study.\",\\n    \"Prof. Dr Ivo Leuschner is cochair and member of SIOP Pathology Panel.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author affiliated with the document named \\'sample.pdf\\'.\",\\n    \"International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document named \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document named \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease cited in the document named \\'sample.pdf\\'.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the document named \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours is a disease mentioned in the document named \\'sample.pdf\\'.\",\\n    \"SIOP\u20132001 protocol is a protocol mentioned in the document named \\'sample.pdf\\'.\",\\n    \"1q is a genomic change mentioned in the document named \\'sample.pdf\\'.\",\\n    \"www.siop-rtsg.eu is a website cited in the document named \\'sample.pdf\\'.\",\\n    \"Renal tumour patients is a group mentioned in the document named \\'sample.pdf\\'.\",\\n    \"Consensus Statement is a document referenced in the document named \\'sample.pdf\\'.\",\\n    \"Wilms tumours is a disease referenced in the document named \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization mentioned in the document named \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease focused on in the UMBRELLA SIOP\u2013RTSG 2016 protocol.\",\\n    \"The UMBRELLA protocol provides treatment guidelines for Wilms tumours.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Marry M. van den Heuvel-Eibrink is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Janna A. Hol is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Kathy Pritchard-Jones is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Harm van Tinteren is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Rhoikos Furtw\\\\u00e4ngler is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Arnauld C. Verschuur is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gordan M. Vujanic is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Ivo Leuschner is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jesper Brok is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christian R\\\\u00fcbe is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Anne M. Smets is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Geert O. Janssens is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jan Godzinski is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gema L. Ram\\\\u00edrez-Villar is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Beatriz de Camargo is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Heidi Segers is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Paola Collini is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Manfred Gessler is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christophe Bergeron is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Filippo Spreafico is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Norbert Graf is affiliated with \\'sample.pdf\\', but the retrieval context does not mention any specific document affiliations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is associated with \\'sample.pdf\\', but the retrieval context does not mention any specific document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP\\\\u2013RTSG is associated with \\'sample.pdf\\', but the retrieval context does not mention any specific document associations.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumour is cited in \\'sample.pdf\\', but the retrieval context does not mention citation in specific documents.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Childhood renal tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP\\\\u20132001 protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 1q is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim that www.siop-rtsg.eu is cited in \\'sample.pdf\\' cannot be confirmed as specific document citation is not mentioned in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Renal tumour patients is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Consensus Statement is referenced in \\'sample.pdf\\', but the retrieval context does not mention any specific document references.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumours is referenced in \\'sample.pdf\\', but the retrieval context does not mention any specific document references.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP\\\\u2013RTSG is mentioned in \\'sample.pdf\\', but the retrieval context does not mention any specific document mentions.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumour is a disease focused on in the UMBRELLA SIOP\\\\u2013RTSG 2016 protocol, but the retrieval context does not mention any specific document focus.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states UMBRELLA protocol provides treatment guidelines for Wilms tumours, but the retrieval context does not mention any specific detail on treatment guidelines.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.75, reason=\"The score is 0.75 because while there are relevant statements such as 'The UMBRELLA protocol facilitates international collaboration in treating Wilms tumours,' the majority of the context focuses on unrelated topics like chemotherapy resistance and specific tumor types, as noted in the irrelevancy points.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0032074499999999997, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is a clinical protocol that addresses treatment and guidelines for Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol provides guidelines for surgery and radiotherapy applicable in Europe.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The International Society of Paediatric Oncology developed the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumours are the subject of the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol facilitates international collaboration in treating Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Chemotherapy-resistant disease can be treated using various treatment strategies.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement \\'Chemotherapy-resistant disease can be treated using various treatment strategies\\' does not directly relate to the UMBRELLA protocol\\'s support for research.\"\\n            },\\n            {\\n                \"statement\": \"SIOP\\\\u2013RTSG is an organization involved in the development of treatment protocols.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"High-risk diffuse anaplasia is a type associated with some Wilms tumours.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement \\'High-risk diffuse anaplasia is a type associated with some Wilms tumours\\' does not explain how the UMBRELLA protocol supports research.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='How does the UMBRELLA protocol plan to support research?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='By integrating biomarker and imaging research with standardized treatment guidelines.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_0', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=True, score=0.6587554333689252, reason=\"The actual output includes relevant elements such as the UMBRELLA protocol, childhood renal tumours, and international collaboration, but it lacks a clear summary of the protocol's aim as stated in the expected output.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028483500000000004, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=True, score=1.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0090069, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the provided text.\",\\n    \"Janna A. Hol is an author associated with the provided text.\",\\n    \"Kathy Pritchard-Jones is an author associated with the provided text.\",\\n    \"Harm van Tinteren is an author associated with the provided text.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the provided text.\",\\n    \"Arnauld C. Verschuur is an author associated with the provided text.\",\\n    \"Gordan M. Vujanic is an author associated with the provided text.\",\\n    \"Ivo Leuschner is an author associated with the provided text.\",\\n    \"Jesper Brok is an author associated with the provided text.\",\\n    \"Christian R\u00fcbe is an author associated with the provided text.\",\\n    \"Anne M. Smets is an author associated with the provided text.\",\\n    \"Geert O. Janssens is an author associated with the provided text.\",\\n    \"Jan Godzinski is an author associated with the provided text.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the provided text.\",\\n    \"Beatriz de Camargo is an author associated with the provided text.\",\\n    \"Heidi Segers is an author associated with the provided text.\",\\n    \"Paola Collini is an author associated with the provided text.\",\\n    \"Manfred Gessler is an author associated with the provided text.\",\\n    \"Christophe Bergeron is an author associated with the provided text.\",\\n    \"Filippo Spreafico is an author associated with the provided text.\",\\n    \"Norbert Graf is an author associated with the provided text.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the provided text.\",\\n    \"SIOP\u2013RTSG is an organization associated with the provided text.\",\\n    \"Wilms tumour is a disease noted in the provided text.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is mentioned in the provided text.\",\\n    \"Childhood renal tumours is a disease noted in the provided text.\",\\n    \"SIOP\u20132001 protocol is mentioned in the provided text.\",\\n    \"1q is a genomic change noted in the provided text.\",\\n    \"The website www.siop-rtsg.eu is referenced in the provided text.\",\\n    \"Renal tumour patients are a patient group referenced in the provided text.\",\\n    \"The Consensus Statement document is mentioned in the provided text.\",\\n    \"Wilms tumours is a disease noted in the provided text.\",\\n    \"The UMBRELLA protocol is mentioned in the provided text.\",\\n    \"Diagnostics is a field noted in the provided text.\",\\n    \"Treatment is a field noted in the provided text.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization referenced in the provided text.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the provided text.\",\\n    \"Doxorubicin is a drug mentioned in the provided text.\",\\n    \"Actinomycin D is a drug mentioned in the provided text.\",\\n    \"Vincristine is a drug mentioned in the provided text.\",\\n    \"The UKW3 trial is a clinical trial referenced in the provided text.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization referenced in the provided text.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the provided text.\",\\n    \"Vincristine is referenced as a chemical in the provided text.\",\\n    \"Actinomycin D is referenced as a chemical in the provided text.\",\\n    \"Doxorubicin is referenced as a chemical in the provided text.\",\\n    \"Event-free survival (EFS) is a medical metric referenced in the provided text.\",\\n    \"Overall survival is a medical metric referenced in the provided text.\",\\n    \"The SIOP-2001 is a clinical trial mentioned in the provided text.\",\\n    \"Large-volume tumours is a medical condition noted in the provided text.\",\\n    \"Stromal tumour types is a medical condition mentioned in the provided text.\",\\n    \"Epithelial tumour types is a medical condition mentioned in the provided text.\",\\n    \"Stage II\u2013III regressive is a medical condition noted in the provided text.\",\\n    \"Mixed is a medical condition referenced in the provided text.\",\\n    \"Focal anaplasia-type tumours is a medical condition referenced in the provided text.\",\\n    \"Log rank P is a statistical measure mentioned in the provided text.\",\\n    \"Blastemal-type tumours is a medical condition mentioned in the provided text.\",\\n    \"The SIOP\u221293\u201301 is a clinical trial noted in the provided text.\",\\n    \"Metastatic disease is a medical condition referenced in the provided text.\",\\n    \"Stage IV disease is a medical condition noted in the provided text.\",\\n    \"Chest CT is a diagnostic test mentioned in the provided text.\",\\n    \"Pulmonary nodules is a medical condition noted in the provided text.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is referenced as a clinical protocol in the provided text.\",\\n    \"CCSK is a medical condition mentioned in the provided text.\",\\n    \"MRTK is a medical condition mentioned in the provided text.\",\\n    \"CMN is a medical condition mentioned in the provided text.\",\\n    \"RCC is a medical condition mentioned in the provided text.\",\\n    \"Event-free survival (EFS) is an entity noted in the provided text.\",\\n    \"Large-volume tumours is an entity noted in the provided text.\",\\n    \"Stage II\u2013III regressive, mixed, and focal anaplasia-type tumours is an entity mentioned in the provided text.\",\\n    \"Metastatic disease is an entity noted in the provided text.\",\\n    \"Stage IV disease is an entity noted in the provided text.\",\\n    \"EFS probability is a metric referenced in the provided text.\",\\n    \"OS probability is a metric noted in the provided text.\",\\n    \"The 60-month EFS \u2013 <500 ml is an outcome mentioned in the provided text.\",\\n    \"The 60-month OS \u2013 <500 ml is an outcome noted in the provided text.\",\\n    \"The 60-month EFS \u2013 500+ ml is an outcome mentioned in the provided text.\",\\n    \"The 60-month OS \u2013 500+ ml is an outcome noted in the provided text.\",\\n    \"HR is a statistic mentioned in the provided text.\",\\n    \"Log\u2013Rank P is a statistic noted in the provided text.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study mentioned in the provided text.\",\\n    \"CT-only nodules is a medical condition referenced in the provided text.\",\\n    \"The COG protocol is a protocol mentioned in the provided text.\",\\n    \"NWTS-4 is a study noted in the provided text.\",\\n    \"NWTS-5 is a study noted in the provided text.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment mentioned in the provided text.\",\\n    \"Pulmonary radiotherapy is a treatment referenced in the provided text.\",\\n    \"The SIOP\u22122001 protocol is mentioned in the provided text.\",\\n    \"AREN0533 is a study noted in the provided text.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment mentioned in the provided text.\",\\n    \"The SIOP database is a database noted in the provided text.\",\\n    \"The 60-month EFS - AVD. <500 ml data point is referenced in the provided text.\",\\n    \"The 60-month OS - AVD. <500 ml data point is referenced in the provided text.\",\\n    \"The 60-month EFS - AV-2. <500 ml data point is referenced in the provided text.\",\\n    \"The 60-month OS - AV-2. <500 ml data point is referenced in the provided text.\",\\n    \"The 60-month EFS - AVD. 500+ ml data point is referenced in the provided text.\",\\n    \"The 60-month OS - AVD. 500+ ml data point is referenced in the provided text.\",\\n    \"The 60-month EFS - AV-2. 500+ ml data point is referenced in the provided text.\",\\n    \"The 60-month OS - AV-2. 500+ ml data point is referenced in the provided text.\",\\n    \"AVD is a treatment mentioned in the provided text.\",\\n    \"AV-2 is a treatment mentioned in the provided text.\",\\n    \"Bilateral Wilms tumour is a condition noted in the provided text.\",\\n    \"ESRD is a condition mentioned in the provided text.\",\\n    \"WAGR syndrome is a condition noted in the provided text.\",\\n    \"Denys-Drash syndrome is a condition mentioned in the provided text.\",\\n    \"UMBRELLA protocol is a treatment protocol referenced in the provided text.\",\\n    \"Group AA is a patient group noted in the provided text.\",\\n    \"Group BB is a patient group noted in the provided text.\",\\n    \"Group CC is a patient group noted in the provided text.\",\\n    \"Wilms tumour is a disease mentioned in the provided text.\",\\n    \"Stage IV WT is a disease stage referenced in the provided text.\",\\n    \"Low-risk disease is a risk category noted in the provided text.\",\\n    \"Intermediate-risk disease is a risk category mentioned in the provided text.\",\\n    \"High-risk disease is a risk category noted in the provided text.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic referenced in the provided text.\",\\n    \"Lung nodules >5mm is a disease characteristic noted in the provided text.\",\\n    \"Other site is a disease characteristic mentioned in the provided text.\",\\n    \"Viable metastasis is a disease characteristic referenced in the provided text.\",\\n    \"Completely necrotic metastasis is a disease characteristic noted in the provided text.\",\\n    \"No evidence of viable tumour is a disease characteristic mentioned in the provided text.\",\\n    \"No evidence of metastasis is a disease characteristic noted in the provided text.\",\\n    \"Metastasis confirmed is a disease characteristic referenced in the provided text.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic noted in the provided text.\",\\n    \"Confirm metastatic disease by histology is a procedure referenced in the provided text.\",\\n    \"AVD150 is a treatment mentioned in the provided text.\",\\n    \"AVD250 is a treatment noted in the provided text.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the provided text.\",\\n    \"Lung or metastasis radiotherapy is a treatment noted in the provided text.\",\\n    \"CT at week 10 is a procedure mentioned in the provided text.\",\\n    \"No radiotherapy to metastases is a treatment noted in the provided text.\",\\n    \"Four-drug regimen is a treatment mentioned in the provided text.\",\\n    \"CDCV is a treatment noted in the provided text.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment mentioned in the provided text.\",\\n    \"Relapsed group CC is a patient group noted in the provided text.\",\\n    \"Initial diffuse anaplasia is a disease characteristic referenced in the provided text.\",\\n    \"Blastemal-type tumours is a disease characteristic noted in the provided text.\",\\n    \"No response to salvage treatment is a condition noted in the provided text.\",\\n    \"Camptothecins is a treatment mentioned in the provided text.\",\\n    \"Irinotecan is a treatment noted in the provided text.\",\\n    \"Topotecan is a treatment mentioned in the provided text.\",\\n    \"Novel compounds is a treatment referenced in the provided text.\",\\n    \"Chemotherapy-resistant disease is a condition mentioned in the provided text.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol noted in the provided text.\",\\n    \"SIOP\u2013RTSG is an organization mentioned in the provided text.\",\\n    \"Innovative Therapies for Children with Cancer consortium is an organization noted in the provided text.\",\\n    \"Stage IV WT is an entity mentioned in the provided text.\",\\n    \"Low-risk disease is an entity noted in the provided text.\",\\n    \"Intermediate-risk disease is an entity mentioned in the provided text.\",\\n    \"High-risk disease is an entity noted in the provided text.\",\\n    \"Confirm metastatic disease by histology is an entity mentioned in the provided text.\",\\n    \"Liver or metastasis radiotherapy is an entity noted in the provided text.\",\\n    \"AVD150 is an entity referenced in the provided text.\",\\n    \"AVD250 is an entity noted in the provided text.\",\\n    \"Pulmonary radiotherapy is an entity referenced in the provided text.\",\\n    \"Four-drug regimen is an entity noted in the provided text.\",\\n    \"SIOP\u2013RTSG is an entity mentioned in the provided text.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is an entity noted in the provided text.\",\\n    \"Radiotherapy is a procedure mentioned in the provided text.\",\\n    \"Surgery is a procedure noted in the provided text.\",\\n    \"Wilms tunure is a disease mentioned in the provided text.\",\\n    \"Adult patients are referenced as a population in the provided text.\",\\n    \"Chemotherapy is a treatment mentioned in the provided text.\",\\n    \"SIOP\u2212RTSG panel is an entity mentioned in the provided text.\",\\n    \"Infant Wilms tumours is a condition subcategory noted in the provided text.\",\\n    \"The clinical guidelines document is referenced in the provided text.\",\\n    \"Nephrectomy is a surgical procedure mentioned in the provided text.\",\\n    \"Congenital mesoblastic nephroma is a condition noted in the provided text.\",\\n    \"Malignant rhabdoid tumours is a condition mentioned in the provided text.\",\\n    \"Actinomycin D is a medication referenced in the provided text.\",\\n    \"Vincristine is a medication noted in the provided text.\",\\n    \"Anaplasia is a condition detail mentioned in the provided text.\",\\n    \"Postoperative chemotherapy is a treatment phase referenced in the provided text.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a treatment regimen noted in the provided text.\",\\n    \"Carboplatin is a medication mentioned in the provided text.\",\\n    \"Cyclophosphamide is a medication noted in the provided text.\",\\n    \"Etoposide is a medication mentioned in the provided text.\",\\n    \"Doxorubicin is a medication noted in the provided text.\",\\n    \"The surgical guidelines document is mentioned in the provided text.\",\\n    \"NSS is a surgical technique mentioned in the provided text.\",\\n    \"Lymph node sampling is a surgical procedure noted in the provided text.\",\\n    \"SIOP\u2212RTSG surgical panel is an entity mentioned in the provided text.\",\\n    \"Nephron-sparing surgery (NSS) classification is a classification system noted in the provided text.\",\\n    \"Surgery is an entity referenced in the provided text.\",\\n    \"Radiotherapy is an entity noted in the provided text.\",\\n    \"Adult patients are an entity noted in the provided text.\",\\n    \"Infant Wilms tumours is an entity mentioned in the provided text.\",\\n    \"Nephrectomy is an entity noted in the provided text.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is an entity mentioned in the provided text.\",\\n    \"Chemotherapy is an entity noted in the provided text.\",\\n    \"Carboplatin is an entity mentioned in the provided text.\",\\n    \"Cyclophosphamide is an entity noted in the provided text.\",\\n    \"Etoposide is an entity referenced in the provided text.\",\\n    \"Surgical guidelines is an entity mentioned in the provided text.\",\\n    \"NSS is an entity noted in the provided text.\",\\n    \"Lymph node sampling is an entity mentioned in the provided text.\",\\n    \"Nephron-sparing surgery (NSS) classification is an entity noted in the provided text.\",\\n    \"Minimally invasive surgery is a procedure noted in the provided text.\",\\n    \"Laparoscopic surgery is a procedure mentioned in the provided text.\",\\n    \"NSS is a procedure mentioned in the provided text.\",\\n    \"Radiotherapy is a treatment mentioned in the provided text.\",\\n    \"Wilms tumours is a condition noted in the provided text.\",\\n    \"The SIOP\u22122001 study is mentioned in the provided text.\",\\n    \"COG\u2013NWTS trials is a study noted in the provided text.\",\\n    \"Proton therapy is a treatment mentioned in the provided text.\",\\n    \"Locoregional disease is a condition noted in the provided text.\",\\n    \"Metastatic disease is a condition mentioned in the provided text.\",\\n    \"Low-risk is a risk level noted in the provided text.\",\\n    \"Intermediate-risk is a risk level mentioned in the provided text.\",\\n    \"High-risk is a risk level noted in the provided text.\",\\n    \"High-risk blastemal-type Wilms tumour is a condition mentioned in the provided text.\",\\n    \"High-risk diffuse anaplasia is a condition noted in the provided text.\",\\n    \"COG\u2013NWTS trials is an entity mentioned in the provided text.\",\\n    \"Proton therapy is an entity noted in the provided text.\",\\n    \"Locoregional disease is an entity mentioned in the provided text.\",\\n    \"Iceland is referenced as a country in the provided text.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the provided text.\",\\n    \"The SIOP renal tumour protocol is a protocol mentioned in the provided text.\",\\n    \"Europe is referenced as a region in the provided text.\",\\n    \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization mentioned in the provided text.\",\\n    \"ExPO-r-Net is a project noted in the provided text.\",\\n    \"Germany is referenced as a country in the provided text.\",\\n    \"Italy is referenced as a country in the provided text.\",\\n    \"The Netherlands is referenced as a country in the provided text.\",\\n    \"Poland is referenced as a country in the provided text.\",\\n    \"Austria is referenced as a country in the provided text.\",\\n    \"France is referenced as a country in the provided text.\",\\n    \"Spain is referenced as a country in the provided text.\",\\n    \"The UK is referenced as a country in the provided text.\",\\n    \"COG is an organization mentioned in the provided text.\",\\n    \"Europe is an entity noted in the provided text.\",\\n    \"International collaboration is an entity mentioned in the provided text.\",\\n    \"Iceland is an entity noted in the provided text.\",\\n    \"Weirich, A. is an author associated with the provided text.\",\\n    \"The Children\u2019s Oncology Group study AREN0533 is a study noted in the provided text.\",\\n    \"SIOP-9/GPOH is a trial mentioned in the provided text.\",\\n    \"Terenziani, M. is an author associated with the provided text.\",\\n    \"Adult Wilms\u2019 tumor is a condition mentioned in the provided text.\",\\n    \"Daw, N. C. is an author associated with the provided text.\",\\n    \"Vincristine and irinotecan is a treatment mentioned in the provided text.\",\\n    \"The Children\u2019s Oncology Group AREN0321 is a study noted in the provided text.\",\\n    \"Ha, T. C. is an author associated with the provided text.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is a treatment mentioned in the provided text.\",\\n    \"Kremens, B. is an author associated with the provided text.\",\\n    \"Autologous stem cell rescue is a treatment mentioned in the provided text.\",\\n    \"Furtwangler, R. is an author associated with the provided text.\",\\n    \"GPOH-nephroblastoma study group is a group mentioned in the provided text.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is a group mentioned in the provided text.\",\\n    \"SIOP WT 2001 is a protocol mentioned in the provided text.\",\\n    \"D\u2019Angio, G. J. is an author associated with the provided text.\",\\n    \"The National Wilms\u2019 Tumor Study is a study noted in the provided text.\",\\n    \"SIOP Pathology Panel is a panel mentioned in the provided text.\",\\n    \"Prof. Dr Ivo Leuschner is a person associated with the provided text.\"\\n] \\n \\nClaims:\\n[\\n    \"The authors of the document are Marry M. van den Heuvel-Eibrink, Janna A. Hol, Kathy Pritchard-Jones, Harm van Tinteren, Rhoikos Furtw\u00e4ngler, Arnauld C. Verschuur, Gordan M. Vujanic, Ivo Leuschner, Jesper Brok, Christian R\u00fcbe, Anne M. Smets, Geert O. Janssens, Jan Godzinski, Gema L. Ram\u00edrez-Villar, Beatriz de Camargo, Heidi Segers, Paola Collini, Manfred Gessler, Christophe Bergeron, Filippo Spreafico, and Norbert Graf.\",\\n    \"The document is titled \\'Consensus Statement\\'.\",\\n    \"The document involves the International Society of Paediatric Oncology \u2013 Renal Tumour Study Group and the SIOP\u2013RTSG.\",\\n    \"The document addresses Wilms tumour and childhood renal tumours.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is mentioned as a protocol related to renal tumours.\",\\n    \"The study investigates treatments for renal tumour patients.\",\\n    \"Doxorubicin, actinomycin D, and vincristine are referenced as drugs associated with the treatments.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization related to the study.\",\\n    \"The SIOP\u22122001 randomized trial is referenced as a clinical trial in the document.\",\\n    \"The authors and organizations mentioned contribute to research regarding Wilms tumour.\",\\n    \"The methods of treatment discussed include vincristine, actinomycin D plus doxorubicin, high-dose chemotherapy, and autologous stem cell transplantation.\",\\n    \"The document discusses low, intermediate, and high-risk disease categories regarding Wilms tumour.\",\\n    \"The relationship between treatment protocols and various patient groups is explored in the document.\",\\n    \"The document covers both diagnostic and treatment fields related to childhood renal tumours.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"idk\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    },\\n    {\\n        \"verdict\": \"yes\",\\n        \"reason\": null\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.6666666666666666, reason=\"The score is 0.67 because while there are relevant statements such as 'UMBRELLA SIOP\u2013RTSG 2016 protocol includes treatment for high-risk kidney cancer' and 'UMBRELLA protocol specifies treatment regimens', the majority of statements do not directly address the primary goal of the UMBRELLA protocol, with mentions like 'ExPO-r-Net' and 'initially treated patients' being irrelevant.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.00343395, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"UMBRELLA SIOP\\\\u2013RTSG 2016 protocol includes treatment for high-risk kidney cancer.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol provides guidelines for surgery.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA protocol provides guidelines for radiotherapy.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumor is included in the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol is applied in Europe.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Children\\\\u2019s Oncology Group study AREN0533 is related to the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"UMBRELLA SIOP-RTSG 2016 protocol includes treatment for various diseases including Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Europe is part of the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"SIOP-2001 randomized trial evaluates drugs including doxorubicin.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"ExPO-r-Net is related to the European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The mention of \\'ExPO-r-Net\\' doesn\\'t provide relevant information regarding the specific goal of the UMBRELLA protocol.\"\\n            },\\n            {\\n                \"statement\": \"SIOP\\\\u20132001 protocol investigates initially treated patients.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The focus on \\'initially treated patients\\' does not address the primary goal of the UMBRELLA protocol.\"\\n            },\\n            {\\n                \"statement\": \"SIOP\\\\u2013RTSG develops clinical trials.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The statement about developing clinical trials does not specifically relate to the goals of the UMBRELLA protocol.\"\\n            },\\n            {\\n                \"statement\": \"Daw, N. C. studied treatment options.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement does not specify relevance to the UMBRELLA protocol\\'s goals.\"\\n            },\\n            {\\n                \"statement\": \"Vincristine treatment is used in pediatric oncology.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"This statement is too general and does not specifically address the UMBRELLA protocol.\"\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol specifies treatment regimens.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What is the primary goal of the UMBRELLA protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='The UMBRELLA protocol aims to standardize the diagnosis and treatment of childhood renal tumours and promote international collaboration.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_1', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.38198259056670736, reason=\"The actual output mentions childhood renal tumours and Wilms tumour, but it lacks a clear focus on 'childhood patients' specifically as outlined in the expected output.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028408499999999994, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=False, score=0.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.011425349999999999, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol.\",\\n    \"Childhood renal tumours are a disease.\",\\n    \"SIOP\u20132001 is a protocol.\",\\n    \"The genomic change 1q is observed in certain conditions.\",\\n    \"www.siop-rtsg.eu is a website.\",\\n    \"Renal tumour patients form a group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours are a disease.\",\\n    \"The UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours are a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed types are a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours is a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules are a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"Eighty percent survival rate is a measure for Bilateral Wilms tumour.\",\\n    \"Surgery is a procedure utilized in various treatments for Wilms tumour.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author associated with the document \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP\u20132001 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"1q is a genomic change mentioned in the document \\'sample.pdf\\'.\",\\n    \"The website www.siop-rtsg.eu is referenced in the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients is a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Consensus Statement is a document referenced in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumours is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Diagnostics is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Treatment is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UKW3 trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a chemical mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a chemical mentioned in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a chemical mentioned in the document \\'sample.pdf\\'.\",\\n    \"Event-free survival (EFS) is a medical metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"Overall survival is a medical metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP-2001 is a Clinical Trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Large-volume tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stromal tumour types is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Epithelial tumour types is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage II\u2013III regressive is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Mixed is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Focal anaplasia-type tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Log rank P is a statistical measure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Blastemal-type tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u221293\u201301 is a Clinical Trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastatic disease is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage IV disease is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chest CT is a diagnostic test mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary nodules is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP-RTSG 2016 protocol is a clinical protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"CCSK is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"MRTK is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"CMN is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"RCC is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"EFS probability is a metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"OS probability is a metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS \u2013 <500 ml is an outcome mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS \u2013 500+ ml is an outcome mentioned in the document \\'sample.pdf\\'.\",\\n    \"HR is a statistic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Log\u2013Rank P is a statistic mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"CT-only nodules is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"COG protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"NWTS-4 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"NWTS-5 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP\u22122001 is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"AREN0533 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP database is a database mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS - AVD. <500 ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS - AVD. <500 ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS - AV-2. <500 ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS - AVD. 500+ ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"AV-2 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Bilateral Wilms tumour is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"ESRD is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"WAGR syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Denys-Drash syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a treatment protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group AA is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group BB is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group CC is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage IV WT is a disease stage mentioned in the document \\'sample.pdf\\'.\",\\n    \"Low-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Intermediate-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules >5mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Other site is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Viable metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Completely necrotic metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastasis confirmed is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Confirm metastatic disease by histology is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD150 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD250 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung or metastasis radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"CT at week 10 is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"No radiotherapy to metastases is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Four-drug regimen is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"CDCV is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Relapsed group CC is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Initial diffuse anaplasia is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Blastemal-type tumours is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No response to salvage treatment is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Camptothecins is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Irinotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Topotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Novel compounds is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chemotherapy-resistant disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA-SIOP-RTSG-2016 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Innovative Therapies for Children with Cancer consortium is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Radiotherapy is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Adult patients is a population mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chemotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u2212RTSG panel is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Infant Wilms tumours is a condition subcategory mentioned in the document \\'sample.pdf\\'.\",\\n    \"Clinical guidelines is a document mentioned in the document \\'sample.pdf\\'.\",\\n    \"Nephrectomy is a surgical procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Congenital mesoblastic nephroma is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Malignant rhabdoid tumours is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Anaplasia is a condition detail mentioned in the document \\'sample.pdf\\'.\",\\n    \"Postoperative chemotherapy is a treatment phase mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is a treatment regimen mentioned in the document \\'sample.pdf\\'.\",\\n    \"Carboplatin is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Cyclophosphamide is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Etoposide is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a medication mentioned in the document \\'sample.pdf\\'.\",\\n    \"Surgical guidelines is a document mentioned in the document \\'sample.pdf\\'.\",\\n    \"NSS is a surgical technique mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lymph node sampling is a surgical procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u2212RTSG surgical panel is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Nephron-sparing surgery (NSS) classification is a classification system mentioned in the document \\'sample.pdf\\'.\",\\n    \"Surgery is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Radiotherapy is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Adult patients is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Infant Wilms tumours is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Nephrectomy is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine and actinomycin D plus doxorubicin is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chemotherapy is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Carboplatin is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Cyclophosphamide is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Etoposide is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Surgical guidelines is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"NSS is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lymph node sampling is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Nephron-sparing surgery (NSS) classification is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Minimally invasive surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Laparoscopic surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"NSS is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumours is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP\u22122001 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"COG\u2013NWTS trials is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"Proton therapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Locoregional disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastatic disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Low-risk is a risk level mentioned in the document \\'sample.pdf\\'.\",\\n    \"Intermediate-risk is a risk level mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk is a risk level mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk blastemal-type Wilms tumour is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk diffuse anaplasia is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"COG\u2013NWTS trials is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Proton therapy is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Locoregional disease is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Iceland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP renal tumour protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Europe is a region mentioned in the document \\'sample.pdf\\'.\",\\n    \"The European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"ExPO-r-Net is a project mentioned in the document \\'sample.pdf\\'.\",\\n    \"Germany is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Italy is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Netherlands is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Poland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Austria is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"France is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Spain is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"COG is an organization mentioned in the document \\'sample.pdf\\'.\",\\n    \"Europe is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"International collaboration is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Iceland is an entity mentioned in the document \\'sample.pdf\\'.\",\\n    \"Weirich, A. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group study AREN0533 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP-9/GPOH is a trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Terenziani, M. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Adult Wilms\u2019 tumor is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Daw, N. C. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine and irinotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group AREN0321 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"Ha, T. C. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"High dose therapy in recurrent Wilms\u2019 tumour is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Kremens, B. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Autologous stem cell rescue is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Furtwangler, R. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"The GPOH-nephroblastoma study group is a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP WT 2001 is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"D\u2019Angio, G. J. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"The National Wilms\u2019 Tumor Study is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP Pathology Panel is a panel mentioned in the document \\'sample.pdf\\'.\",\\n    \"Prof. Dr Ivo Leuschner is a person mentioned in the document \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Marry M. van den Heuvel-Eibrink is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Janna A. Hol is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Kathy Pritchard-Jones is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Harm van Tinteren is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Rhoikos Furtw\\\\u00e4ngler is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Arnauld C. Verschuur is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Gordan M. Vujanic is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Ivo Leuschner is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Jesper Brok is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Christian R\\\\u00fcbe is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Anne M. Smets is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Geert O. Janssens is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Jan Godzinski is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Gema L. Ram\\\\u00edrez-Villar is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Beatriz de Camargo is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Heidi Segers is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Paola Collini is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Manfred Gessler is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Christophe Bergeron is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Filippo Spreafico is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Norbert Graf is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims SIOP\\\\u2013RTSG is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Wilms tumour is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Childhood renal tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims SIOP\\\\u20132001 protocol is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims 1q is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The website www.siop-rtsg.eu is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Renal tumour patients is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The Consensus Statement is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Wilms tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The UMBRELLA protocol is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Diagnostics is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Treatment is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Children\\\\u2019s Oncology Group (COG) is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The SIOP\\\\u22122001 randomized trial is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Doxorubicin is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Actinomycin D is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Vincristine is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The UKW3 trial is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The UK Children\\\\u2019s Cancer and Leukaemia Group (UKCCLG) is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims High-risk, blastemal-type Wilms tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Vincristine is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Actinomycin D is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Doxorubicin is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Event-free survival (EFS) is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Overall survival is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims SIOP-2001 is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Large-volume tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Stromal tumour types is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Epithelial tumour types is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Stage II\\\\u2013III regressive is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Mixed is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Focal anaplasia-type tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Log rank P is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Blastemal-type tumours is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims The SIOP\\\\u221293\\\\u201301 is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Metastatic disease is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Stage IV disease is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Chest CT is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Pulmonary nodules is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims CCSK is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims MRTK is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims CMN is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims RCC is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims EFS probability is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims OS probability is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Eighty percent survival rate is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The actual output claims Surgery is associated with \\'sample.pdf\\', but there is no mention of association with specific documents in the retrieval context.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.7142857142857143, reason=\"The score is 0.71 because while the retrieval context refers to 'renal tumour patients', it lacks direct mention of the specific patient group primarily addressed by the UMBRELLA protocol, as indicated by the irrelevant focus on 'renal tumour patients' and the omission of adult patient distinctions.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.003144, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"The UMBRELLA protocol addresses renal tumour patients.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol includes treatment for childhood renal tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Group AA, Group BB, and Group CC are defined treatment groups in the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol is about adult patients.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context is focused on \\'renal tumour patients\\', not specifically adult patients.\"\\n            },\\n            {\\n                \"statement\": \"Wilms tumour is included in the UMBRELLA protocol.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol has guidelines for surgery and radiotherapy.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The UMBRELLA protocol is a study conducted in the UK.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context does not specify a location; it implies international collaboration.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='Which patient group is primarily addressed by the UMBRELLA protocol?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Childhood patients with renal tumours, particularly those with Wilms tumour.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"]), TestResult(name='test_case_10', success=False, metrics_data=[MetricData(name='Answer Correctness (GEval)', threshold=0.5, success=False, score=0.0, reason='The actual output does not contain any factual information about the percentage of renal tumours in paediatric malignancies, therefore it does not match the expected output.', strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0028399499999999995, verbose_logs='Criteria:\\nNone \\n \\nEvaluation Steps:\\n[\\n    \"Determine whether the actual output is factually correct based on the expected output.\"\\n]'), MetricData(name='Faithfulness', threshold=0.7, success=False, score=0.0, reason=None, strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.012437549999999999, verbose_logs='Truths (limit=None):\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author.\",\\n    \"Janna A. Hol is an author.\",\\n    \"Kathy Pritchard-Jones is an author.\",\\n    \"Harm van Tinteren is an author.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author.\",\\n    \"Arnauld C. Verschuur is an author.\",\\n    \"Gordan M. Vujanic is an author.\",\\n    \"Ivo Leuschner is an author.\",\\n    \"Jesper Brok is an author.\",\\n    \"Christian R\u00fcbe is an author.\",\\n    \"Anne M. Smets is an author.\",\\n    \"Geert O. Janssens is an author.\",\\n    \"Jan Godzinski is an author.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author.\",\\n    \"Beatriz de Camargo is an author.\",\\n    \"Heidi Segers is an author.\",\\n    \"Paola Collini is an author.\",\\n    \"Manfred Gessler is an author.\",\\n    \"Christophe Bergeron is an author.\",\\n    \"Filippo Spreafico is an author.\",\\n    \"Norbert Graf is an author.\",\\n    \"International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Wilms tumour is a disease.\",\\n    \"UMBRELLA SIOP\u2013RTSG 2016 protocol is a protocol.\",\\n    \"Childhood renal tumours is a disease.\",\\n    \"SIOP\u20132001 protocol is a protocol.\",\\n    \"1q is a genomic change.\",\\n    \"www.siop-rtsg.eu is a website.\",\\n    \"Renal tumour patients form a patient group.\",\\n    \"Consensus Statement is a document.\",\\n    \"Wilms tumours is a disease.\",\\n    \"UMBRELLA protocol is a protocol.\",\\n    \"Diagnostics is a field.\",\\n    \"Treatment is a field.\",\\n    \"Children\u2019s Oncology Group (COG) is an organization.\",\\n    \"SIOP\u22122001 randomized trial is a clinical trial.\",\\n    \"Doxorubicin is a drug.\",\\n    \"Actinomycin D is a drug.\",\\n    \"Vincristine is a drug.\",\\n    \"UKW3 trial is a clinical trial.\",\\n    \"UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype.\",\\n    \"Event-free survival (EFS) is a medical metric.\",\\n    \"Overall survival is a medical metric.\",\\n    \"SIOP-2001 is a clinical trial.\",\\n    \"Large-volume tumours are a medical condition.\",\\n    \"Stromal tumour types are a medical condition.\",\\n    \"Epithelial tumour types are a medical condition.\",\\n    \"Stage II\u2013III regressive is a medical condition.\",\\n    \"Mixed is a medical condition.\",\\n    \"Focal anaplasia-type tumours are a medical condition.\",\\n    \"Log rank P is a statistical measure.\",\\n    \"Blastemal-type tumours are a medical condition.\",\\n    \"SIOP\u221293\u201301 is a clinical trial.\",\\n    \"Metastatic disease is a medical condition.\",\\n    \"Stage IV disease is a medical condition.\",\\n    \"Chest CT is a diagnostic test.\",\\n    \"Pulmonary nodules is a medical condition.\",\\n    \"CCSK is a medical condition.\",\\n    \"MRTK is a medical condition.\",\\n    \"CMN is a medical condition.\",\\n    \"RCC is a medical condition.\",\\n    \"EFS probability is a metric.\",\\n    \"OS probability is a metric.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome.\",\\n    \"60-month OS \u2013 <500 ml is an outcome.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome.\",\\n    \"60-month OS \u2013 500+ ml is an outcome.\",\\n    \"HR is a statistic.\",\\n    \"Log\u2013Rank P is a statistic.\",\\n    \"SIOP\u22122001 randomized controlled trial is a study.\",\\n    \"CT-only nodules are a medical condition.\",\\n    \"COG protocol is a protocol.\",\\n    \"NWTS-4 is a study.\",\\n    \"NWTS-5 is a study.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment regimen.\",\\n    \"Pulmonary radiotherapy is a treatment.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment.\",\\n    \"SIOP database is a database.\",\\n    \"60-month EFS - AVD. <500 ml is a data point.\",\\n    \"60-month OS - AVD. <500 ml is a data point.\",\\n    \"60-month EFS - AV-2. <500 ml is a data point.\",\\n    \"60-month OS - AV-2. <500 ml is a data point.\",\\n    \"60-month EFS - AVD. 500+ ml is a data point.\",\\n    \"60-month OS - AVD. 500+ ml is a data point.\",\\n    \"60-month EFS - AV-2. 500+ ml is a data point.\",\\n    \"60-month OS - AV-2. 500+ ml is a data point.\",\\n    \"AVD is a treatment.\",\\n    \"AV-2 is a treatment.\",\\n    \"Bilateral Wilms tumour is a condition.\",\\n    \"ESRD is a condition.\",\\n    \"WAGR syndrome is a condition.\",\\n    \"Denys-Drash syndrome is a condition.\",\\n    \"Group AA is a patient group.\",\\n    \"Group BB is a patient group.\",\\n    \"Group CC is a patient group.\",\\n    \"Stage IV WT is a disease stage.\",\\n    \"Low-risk disease is a risk category.\",\\n    \"Intermediate-risk disease is a risk category.\",\\n    \"High-risk disease is a risk category.\",\\n    \"Lung nodules 3-5mm is a disease characteristic.\",\\n    \"Lung nodules >5mm is a disease characteristic.\",\\n    \"Other site is a disease characteristic.\",\\n    \"Viable metastasis is a disease characteristic.\",\\n    \"Completely necrotic metastasis is a disease characteristic.\",\\n    \"No evidence of viable tumour is a disease characteristic.\",\\n    \"No evidence of metastasis is a disease characteristic.\",\\n    \"Metastasis confirmed is a disease characteristic.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic.\",\\n    \"Confirm metastatic disease by histology is a procedure.\",\\n    \"AVD150 is a treatment.\",\\n    \"AVD250 is a treatment.\",\\n    \"Radiotherapy is a treatment.\",\\n    \"Lung or metastasis radiotherapy is a treatment.\",\\n    \"CT at week 10 is a procedure.\",\\n    \"No radiotherapy to metastases is a treatment.\",\\n    \"Four-drug regimen is a treatment.\",\\n    \"CDCV is a treatment.\",\\n    \"Autologous stem cell rescue (ASCR) is a treatment.\",\\n    \"Initial diffuse anaplasia is a disease characteristic.\",\\n    \"No response to salvage treatment is a condition.\",\\n    \"Camptothecins is a treatment.\",\\n    \"Irinotecan is a treatment.\",\\n    \"Topotecan is a treatment.\",\\n    \"Novel compounds is a treatment.\",\\n    \"SIOP\u2013RTSG is an organization.\",\\n    \"Innovative Therapies for Children with Cancer consortium is an organization.\",\\n    \"Minimally invasive surgery is a procedure.\",\\n    \"Laparoscopic surgery is a procedure.\",\\n    \"NSS is a procedure.\",\\n    \"Wilms tumours is a condition.\",\\n    \"SIOP\u22122001 is a study.\",\\n    \"COG\u2013NWTS trials is a study.\",\\n    \"Proton therapy is a treatment.\",\\n    \"Locoregional disease is a condition.\",\\n    \"Metastatic disease is a condition.\",\\n    \"Low-risk is a risk level.\",\\n    \"Intermediate-risk is a risk level.\",\\n    \"High-risk is a risk level.\",\\n    \"High-risk blastemal-type Wilms tumour is a condition.\",\\n    \"High-risk diffuse anaplasia is a condition.\",\\n    \"Iceland is a country.\",\\n    \"Germany is a country.\",\\n    \"Italy is a country.\",\\n    \"Netherlands is a country.\",\\n    \"Poland is a country.\",\\n    \"Austria is a country.\",\\n    \"France is a country.\",\\n    \"Spain is a country.\",\\n    \"UK is a country.\",\\n    \"ExPO-r-Net is a project.\",\\n    \"University Hospital of Munich is located in Germany.\",\\n    \"Azienda Ospedaliera, Padova is located in Italy.\",\\n    \"Prinses Maxima Centrum, Utrecht is located in Netherlands.\",\\n    \"Marciniak Hospital, Wroclaw is located in Poland.\",\\n    \"St. Anna Kinderspital/CCRI, Vienna is located in Austria.\",\\n    \"Armand Trousseau Hospital, Paris is located in France.\",\\n    \"Hospital Universitario Virgin del Rocio, Seville is located in Spain.\",\\n    \"Great Ormond Street Hospital, London is located in UK.\",\\n    \"Weirich, A. is an author.\",\\n    \"Terenziani, M. is an author.\",\\n    \"Daw, N. C. is an author.\",\\n    \"Ha, T. C. is an author.\",\\n    \"Kremens, B. is an author.\",\\n    \"Furtwangler, R. is an author.\",\\n    \"D\u2019Angio, G. J. is an author.\",\\n    \"SIOP Pathology Panel is a panel.\",\\n    \"Prof. Dr Ivo Leuschner is a person.\"\\n] \\n \\nClaims:\\n[\\n    \"Marry M. van den Heuvel-Eibrink is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Janna A. Hol is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Kathy Pritchard-Jones is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Harm van Tinteren is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Rhoikos Furtw\u00e4ngler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Arnauld C. Verschuur is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gordan M. Vujanic is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Ivo Leuschner is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jesper Brok is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christian R\u00fcbe is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Anne M. Smets is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Geert O. Janssens is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Jan Godzinski is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Gema L. Ram\u00edrez-Villar is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Beatriz de Camargo is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Heidi Segers is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Paola Collini is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Manfred Gessler is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Christophe Bergeron is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Filippo Spreafico is an author associated with the document \\'sample.pdf\\'.\",\\n    \"Norbert Graf is an author associated with the document \\'sample.pdf\\'.\",\\n    \"The International Society of Paediatric Oncology \u2013 Renal Tumour Study Group is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"SIOP\u2013RTSG is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA SIOP\u2013RTSG 2016 protocol is a clinical protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Childhood renal tumours is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u20132001 protocol is a clinical protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"The 1q genomic change is a genomic change mentioned in the document \\'sample.pdf\\'.\",\\n    \"www.siop-rtsg.eu is a website mentioned in the document \\'sample.pdf\\'.\",\\n    \"Renal tumour patients is a patient group associated with the document \\'sample.pdf\\'.\",\\n    \"A Consensus Statement document is associated with the document \\'sample.pdf\\'.\",\\n    \"The UMBRELLA protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"Diagnostics is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"Treatment is a field mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Children\u2019s Oncology Group (COG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Doxorubicin is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Actinomycin D is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine is a drug mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UKW3 trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK Children\u2019s Cancer and Leukaemia Group (UKCCLG) is an organization associated with the document \\'sample.pdf\\'.\",\\n    \"High-risk, blastemal-type Wilms tumours is a disease subtype mentioned in the document \\'sample.pdf\\'.\",\\n    \"Event-free survival (EFS) is a medical metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"Overall survival is a medical metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"Large-volume tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stromal tumour types is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Epithelial tumour types is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage II\u2013III regressive is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Mixed is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Focal anaplasia-type tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Blastemal-type tumours is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u221293\u201301 trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastatic disease is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage IV disease is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chest CT is a diagnostic test mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary nodules is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"CCSK is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"MRTK is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"CMN is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"RCC is a medical condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS \u2013 <500 ml is an outcome metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS \u2013 <500 ml is an outcome metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month EFS \u2013 500+ ml is an outcome metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"60-month OS \u2013 500+ ml is an outcome metric mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 randomized controlled trial is a clinical trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"The CT-only nodules medical condition is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The NWTS-4 study is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The NWTS-5 study is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine, actinomycin D plus doxorubicin is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Pulmonary radiotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-dose chemotherapy and autologous stem cell transplantation is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP database is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Bilateral Wilms tumour is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"ESRD is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"WAGR syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Denys-Drash syndrome is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group AA is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group BB is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Group CC is a patient group mentioned in the document \\'sample.pdf\\'.\",\\n    \"Wilms tumour is a disease mentioned in the document \\'sample.pdf\\'.\",\\n    \"Stage IV WT is a disease stage mentioned in the document \\'sample.pdf\\'.\",\\n    \"Low-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Intermediate-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"High-risk disease is a risk category mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules 3\u20135mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Lung nodules >5mm is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Other site is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Viable metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Completely necrotic metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of metastasis is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastasis confirmed is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"No evidence of viable or necrotic tumour is a disease characteristic mentioned in the document \\'sample.pdf\\'.\",\\n    \"Confirm metastatic disease by histology is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD150 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"AVD250 is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Radiotherapy is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"Adult patients is a population mentioned in the document \\'sample.pdf\\'.\",\\n    \"Chemotherapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"The NSS surgical technique is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Laparoscopic surgery is a procedure mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP\u22122001 study is mentioned in the document \\'sample.pdf\\'.\",\\n    \"The COG\u2013NWTS trials study is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Proton therapy is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Locoregional disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"Metastatic disease is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The high-risk blastemal-type Wilms tumour is a condition mentioned in the document \\'sample.pdf\\'.\",\\n    \"The high-risk diffuse anaplasia condition is mentioned in the document \\'sample.pdf\\'.\",\\n    \"Iceland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Germany is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Italy is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The Netherlands is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Poland is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Austria is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"France is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Spain is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"The UK is a country mentioned in the document \\'sample.pdf\\'.\",\\n    \"Weirich, A. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Children\u2019s Oncology Group study AREN0533 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"SIOP-9/GPOH is a trial mentioned in the document \\'sample.pdf\\'.\",\\n    \"Terenziani, M. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Daw, N. C. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"Vincristine and irinotecan is a treatment mentioned in the document \\'sample.pdf\\'.\",\\n    \"Children\u2019s Oncology Group AREN0321 is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"Ha, T. C. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"The GPOH-nephroblastoma study group is a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP Renal Tumour Study Group (SIOP-RTSG) is a group mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP WT 2001 protocol is a protocol mentioned in the document \\'sample.pdf\\'.\",\\n    \"D\u2019Angio, G. J. is an author mentioned in the document \\'sample.pdf\\'.\",\\n    \"The National Wilms\u2019 Tumor Study is a study mentioned in the document \\'sample.pdf\\'.\",\\n    \"The SIOP Pathology Panel is a panel mentioned in the document \\'sample.pdf\\'.\",\\n    \"Prof. Dr Ivo Leuschner is a person mentioned in the document \\'sample.pdf\\'.\"\\n] \\n \\nVerdicts:\\n[\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Marry M. van den Heuvel-Eibrink is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Janna A. Hol is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Kathy Pritchard-Jones is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Harm van Tinteren is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Rhoikos Furtw\\\\u00e4ngler is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Arnauld C. Verschuur is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gordan M. Vujanic is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Ivo Leuschner is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jesper Brok is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christian R\\\\u00fcbe is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Anne M. Smets is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Geert O. Janssens is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Jan Godzinski is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Gema L. Ram\\\\u00edrez-Villar is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Beatriz de Camargo is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Heidi Segers is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Paola Collini is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Manfred Gessler is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Christophe Bergeron is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Filippo Spreafico is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Norbert Graf is associated with \\'sample.pdf\\', but the retrieval context does not link any authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the International Society of Paediatric Oncology \\\\u2013 Renal Tumour Study Group is associated with \\'sample.pdf\\', but the retrieval context does not link this organization to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP\\\\u2013RTSG is associated with \\'sample.pdf\\', but the retrieval context does not link this organization to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link diseases to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the UMBRELLA SIOP\\\\u2013RTSG 2016 protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not link protocols to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Childhood renal tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not link diseases to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP\\\\u20132001 protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not link protocols to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the 1q genomic change is mentioned in \\'sample.pdf\\', but the retrieval context does not link genomic changes to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states www.siop-rtsg.eu is mentioned in \\'sample.pdf\\', but the retrieval context does not link websites to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states renal tumour patients is associated with \\'sample.pdf\\', but the retrieval context does not link patient groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states a Consensus Statement document is associated with \\'sample.pdf\\', but the retrieval context does not link this document to a specific publication.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the UMBRELLA protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not link protocols to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states diagnostics is a field mentioned in \\'sample.pdf\\', but the retrieval context does not link fields to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states treatment is a field mentioned in \\'sample.pdf\\', but the retrieval context does not link fields to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the Children\\\\u2019s Oncology Group (COG) is associated with \\'sample.pdf\\', but the retrieval context does not link this organization to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP\\\\u22122001 randomized trial is mentioned in \\'sample.pdf\\', but the retrieval context does not link clinical trials to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states doxorubicin is mentioned in \\'sample.pdf\\', but the retrieval context does not link drugs to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states actinomycin D is mentioned in \\'sample.pdf\\', but the retrieval context does not link drugs to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states vincristine is mentioned in \\'sample.pdf\\', but the retrieval context does not link drugs to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the UKW3 trial is mentioned in \\'sample.pdf\\', but the retrieval context does not link clinical trials to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the UK Children\\\\u2019s Cancer and Leukaemia Group (UKCCLG) is associated with \\'sample.pdf\\', but the retrieval context does not link this organization to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states high-risk, blastemal-type Wilms tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not link diseases to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states event-free survival (EFS) is mentioned in \\'sample.pdf\\', but the retrieval context does not link metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states overall survival is mentioned in \\'sample.pdf\\', but the retrieval context does not link metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states large-volume tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states stromal tumour types is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states epithelial tumour types is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states stage II\\\\u2013III regressive is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states mixed is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states focal anaplasia-type tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states blastemal-type tumours is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP\\\\u221293\\\\u201301 trial is mentioned in \\'sample.pdf\\', but the retrieval context does not link clinical trials to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states metastatic disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states stage IV disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states chest CT is mentioned in \\'sample.pdf\\', but the retrieval context does not link diagnostic tests to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states pulmonary nodules is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states CCSK is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states MRTK is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states CMN is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states RCC is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 60-month EFS \\\\u2013 <500 ml is mentioned in \\'sample.pdf\\', but the retrieval context does not link outcome metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 60-month OS \\\\u2013 <500 ml is mentioned in \\'sample.pdf\\', but the retrieval context does not link outcome metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 60-month EFS \\\\u2013 500+ ml is mentioned in \\'sample.pdf\\', but the retrieval context does not link outcome metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states 60-month OS \\\\u2013 500+ ml is mentioned in \\'sample.pdf\\', but the retrieval context does not link outcome metrics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP\\\\u22122001 randomized controlled trial is mentioned in \\'sample.pdf\\', but the retrieval context does not link clinical trials to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the CT-only nodules medical condition is mentioned in \\'sample.pdf\\', but the retrieval context does not link medical conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the NWTS-4 study is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the NWTS-5 study is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states vincristine, actinomycin D plus doxorubicin is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatment regimens to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states pulmonary radiotherapy is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states high-dose chemotherapy and autologous stem cell transplantation is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP database is mentioned in \\'sample.pdf\\', but the retrieval context does not link databases to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states bilateral Wilms tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states ESRD is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states WAGR syndrome is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Denys-Drash syndrome is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Group AA is mentioned in \\'sample.pdf\\', but the retrieval context does not link patient groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Group BB is mentioned in \\'sample.pdf\\', but the retrieval context does not link patient groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Group CC is mentioned in \\'sample.pdf\\', but the retrieval context does not link patient groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Wilms tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link diseases to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states stage IV WT is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease stages to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states low-risk disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link risk categories to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states intermediate-risk disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link risk categories to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states high-risk disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link risk categories to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states lung nodules 3\\\\u20135mm is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states lung nodules >5mm is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states other site is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states viable metastasis is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states completely necrotic metastasis is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states no evidence of viable tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states no evidence of metastasis is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states metastasis confirmed is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states no evidence of viable or necrotic tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link disease characteristics to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states confirm metastatic disease by histology is mentioned in \\'sample.pdf\\', but the retrieval context does not link procedures to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states AVD150 is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states AVD250 is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states radiotherapy is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states surgery is mentioned in \\'sample.pdf\\', but the retrieval context does not link procedures to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states adult patients is mentioned in \\'sample.pdf\\', but the retrieval context does not link populations to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states chemotherapy is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the NSS surgical technique is mentioned in \\'sample.pdf\\', but the retrieval context does not link procedures to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states laparoscopic surgery is mentioned in \\'sample.pdf\\', but the retrieval context does not link procedures to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP\\\\u22122001 study is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the COG\\\\u2013NWTS trials study is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states proton therapy is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states locoregional disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states metastatic disease is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the high-risk blastemal-type Wilms tumour is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the high-risk diffuse anaplasia condition is mentioned in \\'sample.pdf\\', but the retrieval context does not link conditions to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Iceland is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Germany is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Italy is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the Netherlands is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Poland is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Austria is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states France is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Spain is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the UK is mentioned in \\'sample.pdf\\', but the retrieval context does not link countries to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Weirich, A. is mentioned in \\'sample.pdf\\', but the retrieval context does not link authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Children\\\\u2019s Oncology Group study AREN0533 is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states SIOP-9/GPOH is mentioned in \\'sample.pdf\\', but the retrieval context does not link trials to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Terenziani, M. is mentioned in \\'sample.pdf\\', but the retrieval context does not link authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Daw, N. C. is mentioned in \\'sample.pdf\\', but the retrieval context does not link authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states vincristine and irinotecan is mentioned in \\'sample.pdf\\', but the retrieval context does not link treatments to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Children\\\\u2019s Oncology Group AREN0321 is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Ha, T. C. is mentioned in \\'sample.pdf\\', but the retrieval context does not link authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the GPOH-nephroblastoma study group is mentioned in \\'sample.pdf\\', but the retrieval context does not link groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP Renal Tumour Study Group (SIOP-RTSG) is mentioned in \\'sample.pdf\\', but the retrieval context does not link groups to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP WT 2001 protocol is mentioned in \\'sample.pdf\\', but the retrieval context does not link protocols to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states D\\\\u2019Angio, G. J. is mentioned in \\'sample.pdf\\', but the retrieval context does not link authors to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the National Wilms\\\\u2019 Tumor Study is mentioned in \\'sample.pdf\\', but the retrieval context does not link studies to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states the SIOP Pathology Panel is mentioned in \\'sample.pdf\\', but the retrieval context does not link panels to a specific document.\"\\n    },\\n    {\\n        \"verdict\": \"no\",\\n        \"reason\": \"The claim states Prof. Dr Ivo Leuschner is mentioned in \\'sample.pdf\\', but the retrieval context does not link persons to a specific document.\"\\n    }\\n]'), MetricData(name='Contextual Relevancy', threshold=1.0, success=False, score=0.6923076923076923, reason=\"The score is 0.69 because while some statements like 'Wilms tumour is a type of childhood renal tumour' and 'Childhood renal tumours encompass a variety of diseases including Wilms tumours' provide relevant context about renal tumours, many other statements focus on treatment and survival rates, which do not directly address the specific percentage of childhood malignancies represented by renal tumours.\", strict_mode=False, evaluation_model='gpt-4o-mini', error=None, evaluation_cost=0.0033688500000000005, verbose_logs='Verdicts:\\n[\\n    {\\n        \"verdicts\": [\\n            {\\n                \"statement\": \"Wilms tumour is a type of childhood renal tumour.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Childhood renal tumours encompass a variety of diseases including Wilms tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Wilms tumours can be classified as bilateral and unilateral.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Renal tumours are associated with several syndromes such as WAGR syndrome and Denys-Drash syndrome.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"80% of children with bilateral Wilms tumour have other medical issues.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The retrieval context states \\'80% of children with bilateral Wilms tumour have other medical issues\\' which does not pertain to the percentage of childhood malignancies.\"\\n            },\\n            {\\n                \"statement\": \"Childhood renal tumours are treated with chemotherapy, radiotherapy, and surgery.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"There are multiple clinical trials underway for Wilms tumour treatments.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Current research focuses on improving survival rates for renal tumours.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Most children with Wilms\\' tumour respond well to treatment.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"The average age of presentation for Wilms tumours is 3 to 4 years.\",\\n                \"verdict\": \"yes\",\\n                \"reason\": null\\n            },\\n            {\\n                \"statement\": \"Overall survival rates for Wilms tumour are high, often exceeding 80%.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context mentions \\'Overall survival rates for Wilms tumour are high, often exceeding 80%\\' which doesn\\'t inform the specific percentage of childhood malignancies represented by renal tumours.\"\\n            },\\n            {\\n                \"statement\": \"Wilms tumors can lead to later complications due to treatment.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context states \\'Wilms tumors can lead to later complications due to treatment\\' which is not relevant to the percentage of childhood malignancies.\"\\n            },\\n            {\\n                \"statement\": \"Familial Wilms tumours occur in families showing genetic predisposition.\",\\n                \"verdict\": \"no\",\\n                \"reason\": \"The context mentions \\'Familial Wilms tumours occur in families showing genetic predisposition\\' which does not relate to the statistics or percentage of renal tumours.\"\\n            }\\n        ]\\n    }\\n]')], conversational=False, multimodal=False, input='What percentage of childhood malignancies do renal tumours approximately represent?', actual_output=\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\", expected_output='Renal tumours account for about 5% of all paediatric malignancies.', context=None, retrieval_context=[\"[{'nodes': [('sample.pdf', {'type': 'document'}), ('Marry M. van den Heuvel-Eibrink_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Marry M. van den Heuvel-Eibrink'}), ('Janna A. Hol_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Janna A. Hol'}), ('Kathy Pritchard-Jones_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kathy Pritchard-Jones'}), ('Harm van Tinteren_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Harm van Tinteren'}), ('Rhoikos Furtw\u00e4ngler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Rhoikos Furtw\u00e4ngler'}), ('Arnauld C. Verschuur_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Arnauld C. Verschuur'}), ('Gordan M. Vujanic_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gordan M. Vujanic'}), ('Ivo Leuschner_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ivo Leuschner'}), ('Jesper Brok_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jesper Brok'}), ('Christian R\u00fcbe_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christian R\u00fcbe'}), ('Anne M. Smets_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Anne M. Smets'}), ('Geert O. Janssens_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Geert O. Janssens'}), ('Jan Godzinski_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Jan Godzinski'}), ('Gema L. Ram\u00edrez-Villar_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Gema L. Ram\u00edrez-Villar'}), ('Beatriz de Camargo_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Beatriz de Camargo'}), ('Heidi Segers_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Heidi Segers'}), ('Paola Collini_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Paola Collini'}), ('Manfred Gessler_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Manfred Gessler'}), ('Christophe Bergeron_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Christophe Bergeron'}), ('Filippo Spreafico_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Filippo Spreafico'}), ('Norbert Graf_author', {'type': 'entity', 'entity_type': 'author', 'name': 'Norbert Graf'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group'}), ('SIOP\u2013RTSG_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'SIOP\u2013RTSG'}), ('Wilms tumour_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumour'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA SIOP\u2013RTSG 2016 protocol'}), ('childhood renal tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'childhood renal tumours'}), ('SIOP\u20132001 protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u20132001 protocol'}), ('1q_genomic_change', {'type': 'entity', 'entity_type': 'genomic_change', 'name': '1q'}), ('www.siop-rtsg.eu_website', {'type': 'entity', 'entity_type': 'website', 'name': 'www.siop-rtsg.eu'}), ('Marry M. van den Heuvel-Eibrink_entity', {}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {}), ('Janna A. Hol_entity', {}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', {}), ('Wilms tumour_entity', {}), ('childhood renal tumours_entity', {}), ('SIOP\u20132001 protocol_entity', {}), ('1q_entity', {}), ('www.siop-rtsg.eu_entity', {}), ('renal tumour patients_group', {'type': 'entity', 'entity_type': 'group', 'name': 'renal tumour patients'}), ('Consensus Statement_document', {'type': 'entity', 'entity_type': 'document', 'name': 'Consensus Statement'}), ('Wilms tumours_disease', {'type': 'entity', 'entity_type': 'disease', 'name': 'Wilms tumours'}), ('UMBRELLA protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'UMBRELLA protocol'}), ('diagnostics_field', {'type': 'entity', 'entity_type': 'field', 'name': 'diagnostics'}), ('treatment_field', {'type': 'entity', 'entity_type': 'field', 'name': 'treatment'}), ('Children\u2019s Oncology Group (COG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'Children\u2019s Oncology Group (COG)'}), ('SIOP\u22122001 randomized trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'SIOP\u22122001 randomized trial'}), ('doxorubicin_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'doxorubicin'}), ('actinomycin D_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'actinomycin D'}), ('vincristine_drug', {'type': 'entity', 'entity_type': 'drug', 'name': 'vincristine'}), ('UKW3 trial_clinical_trial', {'type': 'entity', 'entity_type': 'clinical_trial', 'name': 'UKW3 trial'}), ('UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'entity', 'entity_type': 'organization', 'name': 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)'}), ('high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'entity', 'entity_type': 'disease_subtype', 'name': 'high-risk, blastemal-type Wilms tumours'}), ('UMBRELLA protocol_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'UMBRELLA protocol'}), ('Wilms tumours_entity', {}), ('SIOP\u22122001 randomized trial_entity', {}), ('doxorubicin_entity', {}), ('vincristine_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'vincristine'}), ('actinomycin D_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'actinomycin D'}), ('doxorubicin_Chemical', {'type': 'entity', 'entity_type': 'Chemical', 'name': 'doxorubicin'}), ('event-free survival (EFS)_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'event-free survival (EFS)'}), ('overall survival_Medical Metric', {'type': 'entity', 'entity_type': 'Medical Metric', 'name': 'overall survival'}), ('SIOP-2001_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP-2001'}), ('large-volume tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'large-volume tumours'}), ('stromal tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stromal tumour types'}), ('epithelial tumour types_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'epithelial tumour types'}), ('stage II\u2013III regressive_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage II\u2013III regressive'}), ('mixed_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'mixed'}), ('focal anaplasia-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'focal anaplasia-type tumours'}), ('Log rank P_Statistical Measure', {'type': 'entity', 'entity_type': 'Statistical Measure', 'name': 'Log rank P'}), ('blastemal-type tumours_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'blastemal-type tumours'}), ('SIOP\u221293\u201301_Clinical Trial', {'type': 'entity', 'entity_type': 'Clinical Trial', 'name': 'SIOP\u221293\u201301'}), ('metastatic disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'metastatic disease'}), ('stage IV disease_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'stage IV disease'}), ('chest CT_Diagnostic Test', {'type': 'entity', 'entity_type': 'Diagnostic Test', 'name': 'chest CT'}), ('pulmonary nodules_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'pulmonary nodules'}), ('UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'entity', 'entity_type': 'Clinical Protocol', 'name': 'UMBRELLA SIOP-RTSG 2016 protocol'}), ('CCSK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CCSK'}), ('MRTK_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'MRTK'}), ('CMN_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'CMN'}), ('RCC_Medical Condition', {'type': 'entity', 'entity_type': 'Medical Condition', 'name': 'RCC'}), ('event-free survival (EFS)_entity', {}), ('large-volume tumours_entity', {}), ('stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {}), ('metastatic disease_entity', {}), ('stage IV disease_entity', {}), ('EFS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'EFS probability'}), ('OS probability_metric', {'type': 'entity', 'entity_type': 'metric', 'name': 'OS probability'}), ('60-month EFS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 <500 ml'}), ('60-month OS \u2013 <500 ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 <500 ml'}), ('60-month EFS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month EFS \u2013 500+ ml'}), ('60-month OS \u2013 500+ ml_outcome', {'type': 'entity', 'entity_type': 'outcome', 'name': '60-month OS \u2013 500+ ml'}), ('HR_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'HR'}), ('Log\u2013Rank P_statistic', {'type': 'entity', 'entity_type': 'statistic', 'name': 'Log\u2013Rank P'}), ('SIOP\u22122001 randomized controlled trial_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001 randomized controlled trial'}), ('CT-only nodules_medical_condition', {'type': 'entity', 'entity_type': 'medical_condition', 'name': 'CT-only nodules'}), ('COG protocol_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'COG protocol'}), ('NWTS-4_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-4'}), ('NWTS-5_study', {'type': 'entity', 'entity_type': 'study', 'name': 'NWTS-5'}), ('vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine, actinomycin D plus doxorubicin'}), ('pulmonary radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'pulmonary radiotherapy'}), ('SIOP\u22122001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP\u22122001'}), ('AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'AREN0533'}), ('high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high-dose chemotherapy and autologous stem cell transplantation'}), ('SIOP database_database', {'type': 'entity', 'entity_type': 'database', 'name': 'SIOP database'}), ('COG protocol_entity', {}), ('CT-only nodules_entity', {}), ('SIOP\u22122001_entity', {}), ('high-dose chemotherapy and autologous stem cell transplantation_entity', {}), ('AREN0533_entity', {}), ('SIOP database_entity', {}), ('60-month EFS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. <500 ml'}), ('60-month OS - AVD. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. <500 ml'}), ('60-month EFS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. <500 ml'}), ('60-month OS - AV-2. <500 ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. <500 ml'}), ('60-month EFS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AVD. 500+ ml'}), ('60-month OS - AVD. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AVD. 500+ ml'}), ('60-month EFS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month EFS - AV-2. 500+ ml'}), ('60-month OS - AV-2. 500+ ml_data_point', {'type': 'entity', 'entity_type': 'data_point', 'name': '60-month OS - AV-2. 500+ ml'}), ('AVD_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AVD'}), ('AV-2_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'AV-2'}), ('Bilateral Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Bilateral Wilms tumour'}), ('ESRD_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'ESRD'}), ('WAGR syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'WAGR syndrome'}), ('Denys-Drash syndrome_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Denys-Drash syndrome'}), ('UMBRELLA protocol_treatment_protocol', {'type': 'entity', 'entity_type': 'treatment_protocol', 'name': 'UMBRELLA protocol'}), ('Group AA_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group AA'}), ('Group BB_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group BB'}), ('Group CC_patient_group', {'type': 'entity', 'entity_type': 'patient_group', 'name': 'Group CC'}), ('Group AA_entity', {}), ('Group BB_entity', {}), ('Group CC_entity', {}), ('Wilms tumour_Disease', {'type': 'entity', 'entity_type': 'Disease', 'name': 'Wilms tumour'}), ('stage IV WT_Disease Stage', {'type': 'entity', 'entity_type': 'Disease Stage', 'name': 'stage IV WT'}), ('low-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'low-risk disease'}), ('intermediate-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'intermediate-risk disease'}), ('high-risk disease_Risk Category', {'type': 'entity', 'entity_type': 'Risk Category', 'name': 'high-risk disease'}), ('lung nodules 3\u20135mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules 3\u20135mm'}), ('lung nodules >5mm_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'lung nodules >5mm'}), ('other site_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'other site'}), ('viable metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'viable metastasis'}), ('completely necrotic metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'completely necrotic metastasis'}), ('no evidence of viable tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable tumour'}), ('no evidence of metastasis_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of metastasis'}), ('metastasis confirmed_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'metastasis confirmed'}), ('no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'no evidence of viable or necrotic tumour'}), ('confirm metastatic disease by histology_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'confirm metastatic disease by histology'}), ('AVD150_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD150'}), ('AVD250_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'AVD250'}), ('pulmonary radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'pulmonary radiotherapy'}), ('lung or metastasis radiotherapy_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'lung or metastasis radiotherapy'}), ('CT at week 10_Procedure', {'type': 'entity', 'entity_type': 'Procedure', 'name': 'CT at week 10'}), ('no radiotherapy to metastases_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'no radiotherapy to metastases'}), ('four-drug regimen_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'four-drug regimen'}), ('CDCV_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'CDCV'}), ('autologous stem cell rescue (ASCR)_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'autologous stem cell rescue (ASCR)'}), ('relapsed group CC_Patient Group', {'type': 'entity', 'entity_type': 'Patient Group', 'name': 'relapsed group CC'}), ('initial diffuse anaplasia_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'initial diffuse anaplasia'}), ('blastemal-type tumours_Disease Characteristic', {'type': 'entity', 'entity_type': 'Disease Characteristic', 'name': 'blastemal-type tumours'}), ('no response to salvage treatment_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'no response to salvage treatment'}), ('camptothecins_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'camptothecins'}), ('irinotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'irinotecan'}), ('topotecan_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'topotecan'}), ('novel compounds_Treatment', {'type': 'entity', 'entity_type': 'Treatment', 'name': 'novel compounds'}), ('chemotherapy-resistant disease_Condition', {'type': 'entity', 'entity_type': 'Condition', 'name': 'chemotherapy-resistant disease'}), ('UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA-SIOP-RTSG-2016 protocol'}), ('SIOP\u2013RTSG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'SIOP\u2013RTSG'}), ('Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'Innovative Therapies for Children with Cancer consortium'}), ('stage IV WT_entity', {}), ('low-risk disease_entity', {}), ('intermediate-risk disease_entity', {}), ('high-risk disease_entity', {}), ('confirm metastatic disease by histology_entity', {}), ('liver or metastasis radiotherapy_entity', {}), ('AVD150_entity', {}), ('AVD250_entity', {}), ('pulmonary radiotherapy_entity', {}), ('four-drug regimen_entity', {}), ('SIOP\u2013RTSG_entity', {}), ('UMBRELLA-SIOP-RTSG-2016 protocol_entity', {}), ('radiotherapy_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'radiotherapy'}), ('surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'surgery'}), ('Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumour'}), ('adult patients_population', {'type': 'entity', 'entity_type': 'population', 'name': 'adult patients'}), ('chemotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'chemotherapy'}), ('SIOP\u2212RTSG panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG panel'}), ('Infant Wilms tumours_condition_subcategory', {'type': 'entity', 'entity_type': 'condition_subcategory', 'name': 'Infant Wilms tumours'}), ('clinical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'clinical guidelines'}), ('nephrectomy_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'nephrectomy'}), ('congenital mesoblastic nephroma_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'congenital mesoblastic nephroma'}), ('malignant rhabdoid tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'malignant rhabdoid tumours'}), ('actinomycin D_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'actinomycin D'}), ('vincristine_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'vincristine'}), ('anaplasia_condition_detail', {'type': 'entity', 'entity_type': 'condition_detail', 'name': 'anaplasia'}), ('postoperative chemotherapy_treatment_phase', {'type': 'entity', 'entity_type': 'treatment_phase', 'name': 'postoperative chemotherapy'}), ('vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'entity', 'entity_type': 'treatment_regimen', 'name': 'vincristine and actinomycin D plus doxorubicin'}), ('carboplatin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'carboplatin'}), ('cyclophosphamide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'cyclophosphamide'}), ('etoposide_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'etoposide'}), ('doxorubicin_medication', {'type': 'entity', 'entity_type': 'medication', 'name': 'doxorubicin'}), ('surgical guidelines_document', {'type': 'entity', 'entity_type': 'document', 'name': 'surgical guidelines'}), ('NSS_surgical_technique', {'type': 'entity', 'entity_type': 'surgical_technique', 'name': 'NSS'}), ('lymph node sampling_surgical_procedure', {'type': 'entity', 'entity_type': 'surgical_procedure', 'name': 'lymph node sampling'}), ('SIOP\u2212RTSG surgical panel_entity', {'type': 'entity', 'entity_type': 'entity', 'name': 'SIOP\u2212RTSG surgical panel'}), ('nephron-sparing surgery (NSS) classification_classification_system', {'type': 'entity', 'entity_type': 'classification_system', 'name': 'nephron-sparing surgery (NSS) classification'}), ('surgery_entity', {}), ('radiotherapy_entity', {}), ('adult patients_entity', {}), ('Infant Wilms tumours_entity', {}), ('nephrectomy_entity', {}), ('vincristine and actinomycin D plus doxorubicin_entity', {}), ('chemotherapy_entity', {}), ('carboplatin_entity', {}), ('cyclophosphamide_entity', {}), ('etoposide_entity', {}), ('surgical guidelines_entity', {}), ('NSS_entity', {}), ('lymph node sampling_entity', {}), ('nephron-sparing surgery (NSS) classification_entity', {}), ('minimally invasive surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'minimally invasive surgery'}), ('laparoscopic surgery_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'laparoscopic surgery'}), ('NSS_procedure', {'type': 'entity', 'entity_type': 'procedure', 'name': 'NSS'}), ('radiotherapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'radiotherapy'}), ('Wilms tumours_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Wilms tumours'}), ('SIOP\u22122001_study', {'type': 'entity', 'entity_type': 'study', 'name': 'SIOP\u22122001'}), ('COG\u2013NWTS trials_study', {'type': 'entity', 'entity_type': 'study', 'name': 'COG\u2013NWTS trials'}), ('proton therapy_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'proton therapy'}), ('locoregional disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'locoregional disease'}), ('metastatic disease_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'metastatic disease'}), ('low-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'low-risk'}), ('intermediate-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'intermediate-risk'}), ('high-risk_risk_level', {'type': 'entity', 'entity_type': 'risk_level', 'name': 'high-risk'}), ('high-risk blastemal-type Wilms tumour_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk blastemal-type Wilms tumour'}), ('high-risk diffuse anaplasia_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'high-risk diffuse anaplasia'}), ('COG\u2013NWTS trials_entity', {}), ('proton therapy_entity', {}), ('locoregional disease_entity', {}), ('Iceland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Iceland'}), ('UMBRELLA protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'UMBRELLA protocol'}), ('SIOP renal tumour protocol_Protocol', {'type': 'entity', 'entity_type': 'Protocol', 'name': 'SIOP renal tumour protocol'}), ('Europe_Region', {'type': 'entity', 'entity_type': 'Region', 'name': 'Europe'}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment'}), ('ExPO-r-Net_Project', {'type': 'entity', 'entity_type': 'Project', 'name': 'ExPO-r-Net'}), ('Germany_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Germany'}), ('Italy_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Italy'}), ('Netherlands_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Netherlands'}), ('Poland_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Poland'}), ('Austria_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Austria'}), ('France_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'France'}), ('Spain_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'Spain'}), ('UK_Country', {'type': 'entity', 'entity_type': 'Country', 'name': 'UK'}), ('COG_Organization', {'type': 'entity', 'entity_type': 'Organization', 'name': 'COG'}), ('Europe_entity', {}), ('international collaboration_entity', {}), ('Iceland_entity', {}), ('Weirich, A._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Weirich, A.'}), ('Children\u2019s Oncology Group study AREN0533_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group study AREN0533'}), ('SIOP-9/GPOH_trial', {'type': 'entity', 'entity_type': 'trial', 'name': 'SIOP-9/GPOH'}), ('Terenziani, M._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Terenziani, M.'}), ('Adult Wilms\u2019 tumor_condition', {'type': 'entity', 'entity_type': 'condition', 'name': 'Adult Wilms\u2019 tumor'}), ('Daw, N. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Daw, N. C.'}), ('vincristine and irinotecan_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'vincristine and irinotecan'}), ('Children\u2019s Oncology Group AREN0321_study', {'type': 'entity', 'entity_type': 'study', 'name': 'Children\u2019s Oncology Group AREN0321'}), ('Ha, T. C._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Ha, T. C.'}), ('high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'high dose therapy in recurrent Wilms\u2019 tumour'}), ('Kremens, B._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Kremens, B.'}), ('autologous stem cell rescue_treatment', {'type': 'entity', 'entity_type': 'treatment', 'name': 'autologous stem cell rescue'}), ('Furtwangler, R._author', {'type': 'entity', 'entity_type': 'author', 'name': 'Furtwangler, R.'}), ('GPOH-nephroblastoma study group_group', {'type': 'entity', 'entity_type': 'group', 'name': 'GPOH-nephroblastoma study group'}), ('SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'entity', 'entity_type': 'group', 'name': 'SIOP Renal Tumour Study Group (SIOP-RTSG)'}), ('SIOP WT 2001_protocol', {'type': 'entity', 'entity_type': 'protocol', 'name': 'SIOP WT 2001'}), ('D\u2019Angio, G. J._author', {'type': 'entity', 'entity_type': 'author', 'name': 'D\u2019Angio, G. J.'}), ('National Wilms\u2019 Tumor Study_study', {'type': 'entity', 'entity_type': 'study', 'name': 'National Wilms\u2019 Tumor Study'}), ('SIOP Pathology Panel_panel', {'type': 'entity', 'entity_type': 'panel', 'name': 'SIOP Pathology Panel'}), ('Prof. Dr Ivo Leuschner_person', {'type': 'entity', 'entity_type': 'person', 'name': 'Prof. Dr Ivo Leuschner'})], 'edges': [('sample.pdf', 'Marry M. van den Heuvel-Eibrink_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Janna A. Hol_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kathy Pritchard-Jones_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Harm van Tinteren_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Rhoikos Furtw\u00e4ngler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Arnauld C. Verschuur_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gordan M. Vujanic_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ivo Leuschner_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jesper Brok_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christian R\u00fcbe_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Anne M. Smets_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Geert O. Janssens_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Jan Godzinski_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Gema L. Ram\u00edrez-Villar_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Beatriz de Camargo_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Heidi Segers_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Paola Collini_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Manfred Gessler_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Christophe Bergeron_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Filippo Spreafico_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Norbert Graf_author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'childhood renal tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u20132001 protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', '1q_genomic_change', {'type': 'contains', 'page': 1}), ('sample.pdf', 'www.siop-rtsg.eu_website', {'type': 'contains', 'page': 1}), ('sample.pdf', 'renal tumour patients_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Consensus Statement_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'diagnostics_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'treatment_field', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group (COG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_drug', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UKW3 trial_clinical_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK Children\u2019s Cancer and Leukaemia Group (UKCCLG)_organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk, blastemal-type Wilms tumours_disease_subtype', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_Chemical', {'type': 'contains', 'page': 1}), ('sample.pdf', 'event-free survival (EFS)_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'overall survival_Medical Metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-2001_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'large-volume tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stromal tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'epithelial tumour types_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage II\u2013III regressive_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'mixed_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'focal anaplasia-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log rank P_Statistical Measure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u221293\u201301_Clinical Trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV disease_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chest CT_Diagnostic Test', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary nodules_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA SIOP-RTSG 2016 protocol_Clinical Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CCSK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'MRTK_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CMN_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'RCC_Medical Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'EFS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', 'OS probability_metric', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 <500 ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS \u2013 500+ ml_outcome', {'type': 'contains', 'page': 1}), ('sample.pdf', 'HR_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Log\u2013Rank P_statistic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001 randomized controlled trial_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT-only nodules_medical_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG protocol_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-4_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NWTS-5_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine, actinomycin D plus doxorubicin_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-dose chemotherapy and autologous stem cell transplantation_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP database_database', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. <500 ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AVD. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month EFS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', '60-month OS - AV-2. 500+ ml_data_point', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AV-2_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Bilateral Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ESRD_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'WAGR syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Denys-Drash syndrome_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_treatment_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group AA_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group BB_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Group CC_patient_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_Disease', {'type': 'contains', 'page': 1}), ('sample.pdf', 'stage IV WT_Disease Stage', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk disease_Risk Category', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules 3\u20135mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung nodules >5mm_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'other site_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'viable metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'completely necrotic metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of metastasis_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastasis confirmed_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no evidence of viable or necrotic tumour_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'confirm metastatic disease by histology_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD150_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'AVD250_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'pulmonary radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lung or metastasis radiotherapy_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CT at week 10_Procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no radiotherapy to metastases_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'four-drug regimen_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'CDCV_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue (ASCR)_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'relapsed group CC_Patient Group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'initial diffuse anaplasia_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'blastemal-type tumours_Disease Characteristic', {'type': 'contains', 'page': 1}), ('sample.pdf', 'no response to salvage treatment_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'camptothecins_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'irinotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'topotecan_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'novel compounds_Treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy-resistant disease_Condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA-SIOP-RTSG-2016 protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2013RTSG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Innovative Therapies for Children with Cancer consortium_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'adult patients_population', {'type': 'contains', 'page': 1}), ('sample.pdf', 'chemotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Infant Wilms tumours_condition_subcategory', {'type': 'contains', 'page': 1}), ('sample.pdf', 'clinical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephrectomy_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'congenital mesoblastic nephroma_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'malignant rhabdoid tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'actinomycin D_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'anaplasia_condition_detail', {'type': 'contains', 'page': 1}), ('sample.pdf', 'postoperative chemotherapy_treatment_phase', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and actinomycin D plus doxorubicin_treatment_regimen', {'type': 'contains', 'page': 1}), ('sample.pdf', 'carboplatin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'cyclophosphamide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'etoposide_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'doxorubicin_medication', {'type': 'contains', 'page': 1}), ('sample.pdf', 'surgical guidelines_document', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_surgical_technique', {'type': 'contains', 'page': 1}), ('sample.pdf', 'lymph node sampling_surgical_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'contains', 'page': 1}), ('sample.pdf', 'nephron-sparing surgery (NSS) classification_classification_system', {'type': 'contains', 'page': 1}), ('sample.pdf', 'minimally invasive surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'laparoscopic surgery_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'NSS_procedure', {'type': 'contains', 'page': 1}), ('sample.pdf', 'radiotherapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Wilms tumours_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP\u22122001_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG\u2013NWTS trials_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'proton therapy_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'locoregional disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'metastatic disease_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'low-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'intermediate-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk_risk_level', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk blastemal-type Wilms tumour_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high-risk diffuse anaplasia_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Iceland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UMBRELLA protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP renal tumour protocol_Protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Europe_Region', {'type': 'contains', 'page': 1}), ('sample.pdf', 'European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'ExPO-r-Net_Project', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Germany_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Italy_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Netherlands_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Poland_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Austria_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'France_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Spain_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'UK_Country', {'type': 'contains', 'page': 1}), ('sample.pdf', 'COG_Organization', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Weirich, A._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group study AREN0533_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP-9/GPOH_trial', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Terenziani, M._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Adult Wilms\u2019 tumor_condition', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Daw, N. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'vincristine and irinotecan_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Children\u2019s Oncology Group AREN0321_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Ha, T. C._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'high dose therapy in recurrent Wilms\u2019 tumour_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Kremens, B._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'autologous stem cell rescue_treatment', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Furtwangler, R._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'GPOH-nephroblastoma study group_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Renal Tumour Study Group (SIOP-RTSG)_group', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP WT 2001_protocol', {'type': 'contains', 'page': 1}), ('sample.pdf', 'D\u2019Angio, G. J._author', {'type': 'contains', 'page': 1}), ('sample.pdf', 'National Wilms\u2019 Tumor Study_study', {'type': 'contains', 'page': 1}), ('sample.pdf', 'SIOP Pathology Panel_panel', {'type': 'contains', 'page': 1}), ('sample.pdf', 'Prof. Dr Ivo Leuschner_person', {'type': 'contains', 'page': 1}), ('Marry M. van den Heuvel-Eibrink_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'successor_of'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', '1q_entity', {'type': 'relation', 'relation_type': 'research_focus'}), ('UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', 'www.siop-rtsg.eu_entity', {'type': 'relation', 'relation_type': 'available_on'}), ('Janna A. Hol_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'contributor'}), ('International Society of Paediatric Oncology \u2013 Renal Tumour Study Group_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'developer'}), ('Wilms tumour_entity', 'UMBRELLA SIOP\u2013RTSG 2016 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('Wilms tumour_entity', 'adult patients_entity', {'type': 'relation', 'relation_type': 'affects'}), ('Wilms tumour_entity', 'Infant Wilms tumours_entity', {'type': 'relation', 'relation_type': 'includes'}), ('childhood renal tumours_entity', 'SIOP\u20132001 protocol_entity', {'type': 'relation', 'relation_type': 'subject_of'}), ('UMBRELLA protocol_entity', 'Wilms tumours_entity', {'type': 'relation', 'relation_type': 'is_protocol_for'}), ('UMBRELLA protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('UMBRELLA protocol_entity', 'Group AA_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group BB_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'Group CC_entity', {'type': 'relation', 'relation_type': 'defines_treatment_for'}), ('UMBRELLA protocol_entity', 'surgery_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'radiotherapy_entity', {'type': 'relation', 'relation_type': 'provides guidelines for'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG panel_entity', {'type': 'relation', 'relation_type': 'recommends consulting'}), ('UMBRELLA protocol_entity', 'surgical guidelines_entity', {'type': 'relation', 'relation_type': 'specifies'}), ('UMBRELLA protocol_entity', 'lymph node sampling_entity', {'type': 'relation', 'relation_type': 'emphasizes importance of'}), ('UMBRELLA protocol_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'adopts'}), ('UMBRELLA protocol_entity', 'SIOP\u2212RTSG surgical panel_entity', {'type': 'relation', 'relation_type': 'recommends discussion for NSS'}), ('UMBRELLA protocol_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'guides treatment for'}), ('UMBRELLA protocol_entity', 'Europe_entity', {'type': 'relation', 'relation_type': 'applied in'}), ('UMBRELLA protocol_entity', 'SIOP\u2013RTSG_entity', {'type': 'relation', 'relation_type': 'standardized by'}), ('UMBRELLA protocol_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'facilitates'}), ('SIOP\u22122001 randomized trial_entity', 'doxorubicin_entity', {'type': 'relation', 'relation_type': 'investigates_drug'}), ('doxorubicin_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'recommended_for'}), ('doxorubicin_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'included_in'}), ('doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('event-free survival (EFS)_entity', 'large-volume tumours_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('large-volume tumours_entity', 'stage II\u2013III regressive, mixed, and focal anaplasia-type tumours_entity', {'type': 'relation', 'relation_type': 'subset_of'}), ('metastatic disease_entity', 'stage IV disease_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('COG protocol_entity', 'CT-only nodules_entity', {'type': 'relation', 'relation_type': 'includes'}), ('SIOP\u22122001_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'considers'}), ('AREN0533_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'studies'}), ('SIOP database_entity', 'high-dose chemotherapy and autologous stem cell transplantation_entity', {'type': 'relation', 'relation_type': 'captures_outcome_of'}), ('stage IV WT_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a stage of'}), ('low-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('intermediate-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('high-risk disease_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is associated with'}), ('confirm metastatic disease by histology_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a procedure for'}), ('liver or metastasis radiotherapy_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD150_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('AVD250_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('pulmonary radiotherapy_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('four-drug regimen_entity', 'high-risk disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA-SIOP-RTSG-2016 protocol_entity', {'type': 'relation', 'relation_type': 'publishes'}), ('SIOP\u2013RTSG_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'developed'}), ('surgery_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'addressed_in'}), ('radiotherapy_entity', 'SIOP\u22122001_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'COG\u2013NWTS trials_entity', {'type': 'relation', 'relation_type': 'was_refined_based_on'}), ('radiotherapy_entity', 'locoregional disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('radiotherapy_entity', 'metastatic disease_entity', {'type': 'relation', 'relation_type': 'used_for'}), ('Infant Wilms tumours_entity', 'nephrectomy_entity', {'type': 'relation', 'relation_type': 'considered for primary surgery'}), ('vincristine and actinomycin D plus doxorubicin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'is a type of'}), ('carboplatin_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('cyclophosphamide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('etoposide_entity', 'chemotherapy_entity', {'type': 'relation', 'relation_type': 'used in'}), ('NSS_entity', 'Wilms tumour_entity', {'type': 'relation', 'relation_type': 'acceptable for treatment of'}), ('NSS_entity', 'nephron-sparing surgery (NSS) classification_entity', {'type': 'relation', 'relation_type': 'subject to'}), ('proton therapy_entity', 'UMBRELLA protocol_entity', {'type': 'relation', 'relation_type': 'needs_investigation_before_implementation_in'}), ('Iceland_entity', 'international collaboration_entity', {'type': 'relation', 'relation_type': 'part of'})]}, {'nodes': [('Consensus Statement_entity', {}), ('renal tumour patients_entity', {})], 'edges': [('Consensus Statement_entity', 'renal tumour patients_entity', {'type': 'relation', 'relation_type': 'targets'})]}, {'nodes': [('vincristine_entity', {}), ('postoperative chemotherapy_entity', {}), ('actinomycin D_entity', {}), ('UKW3 trial_entity', {})], 'edges': [('vincristine_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('actinomycin D_entity', 'postoperative chemotherapy_entity', {'type': 'relation', 'relation_type': 'included in'}), ('UKW3 trial_entity', 'actinomycin D_entity', {'type': 'relation', 'relation_type': 'supports_use_of'}), ('UKW3 trial_entity', 'vincristine_entity', {'type': 'relation', 'relation_type': 'supports_use_of'})]}, {'nodes': [('vincristine and actinomycin D without doxorubicin_entity', {}), ('SIOP-2001_entity', {})], 'edges': [('vincristine and actinomycin D without doxorubicin_entity', 'SIOP-2001_entity', {'type': 'relation', 'relation_type': 'used_in'})]}, {'nodes': [('stromal tumour types and epithelial tumour types_entity', {}), ('excellent prognosis_entity', {})], 'edges': [('stromal tumour types and epithelial tumour types_entity', 'excellent prognosis_entity', {'type': 'relation', 'relation_type': 'have'})]}, {'nodes': [('blastemal-type tumours_entity', {}), ('SIOP-2001 and SIOP\u221293\u201301_entity', {})], 'edges': [('blastemal-type tumours_entity', 'SIOP-2001 and SIOP\u221293\u201301_entity', {'type': 'relation', 'relation_type': 'compared_in'})]}, {'nodes': [('chest CT_entity', {}), ('pulmonary nodules_entity', {})], 'edges': [('chest CT_entity', 'pulmonary nodules_entity', {'type': 'relation', 'relation_type': 'detects'})]}, {'nodes': [('CCSK, MRTK, CMN, RCC_entity', {}), ('UMBRELLA SIOP-RTSG 2016 protocol_entity', {})], 'edges': [('UMBRELLA SIOP-RTSG 2016 protocol_entity', 'CCSK, MRTK, CMN, RCC_entity', {'type': 'relation', 'relation_type': 'includes_treatment_for'})]}, {'nodes': [('SIOP\u22122001 randomized controlled trial_entity', {}), ('EFS probability_entity', {}), ('HR_entity', {}), ('OS probability_entity', {}), ('60-month EFS \u2013 <500 ml_entity', {}), ('60-month EFS \u2013 500+ ml_entity', {}), ('60-month OS \u2013 <500 ml_entity', {}), ('60-month OS \u2013 500+ ml_entity', {})], 'edges': [('SIOP\u22122001 randomized controlled trial_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('SIOP\u22122001 randomized controlled trial_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'evaluates'}), ('HR_entity', '60-month EFS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('HR_entity', '60-month OS \u2013 500+ ml_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS \u2013 <500 ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month EFS \u2013 500+ ml_entity', 'EFS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 <500 ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'}), ('60-month OS \u2013 500+ ml_entity', 'OS probability_entity', {'type': 'relation', 'relation_type': 'contributes_to'})]}, {'nodes': [('NWTS-4_entity', {}), ('vincristine, actinomycin D plus doxorubicin_entity', {}), ('NWTS-5_entity', {})], 'edges': [('NWTS-4_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'}), ('NWTS-5_entity', 'vincristine, actinomycin D plus doxorubicin_entity', {'type': 'relation', 'relation_type': 'tested'})]}, {'nodes': [('60-month OS - AVD. <500 ml_entity', {}), ('actinomycin D, vincristine and doxorubicin_entity', {}), ('60-month EFS - AVD. <500 ml_entity', {}), ('AVD_entity', {})], 'edges': [('60-month OS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month EFS - AVD. <500 ml_entity', 'AVD_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AVD_entity', 'actinomycin D, vincristine and doxorubicin_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('60-month EFS - AV-2. <500 ml_entity', {}), ('60-month OS - AV-2. <500 ml_entity', {}), ('actinomycin D, vincristine (27 weeks)_entity', {}), ('AV-2_entity', {})], 'edges': [('60-month EFS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('60-month OS - AV-2. <500 ml_entity', 'AV-2_entity', {'type': 'relation', 'relation_type': 'associated_with'}), ('AV-2_entity', 'actinomycin D, vincristine (27 weeks)_entity', {'type': 'relation', 'relation_type': 'consists_of'})]}, {'nodes': [('80%_entity', {}), ('Bilateral Wilms tumour_entity', {}), ('ESRD_entity', {})], 'edges': [('Bilateral Wilms tumour_entity', 'ESRD_entity', {'type': 'relation', 'relation_type': 'can_cause'}), ('Bilateral Wilms tumour_entity', '80%_entity', {'type': 'relation', 'relation_type': 'has_survival_rate'})]}, {'nodes': [('CDCV_entity', {}), ('viable metastasis_entity', {})], 'edges': [('CDCV_entity', 'viable metastasis_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('camptothecins_entity', {}), ('autologous stem cell rescue (ASCR)_entity', {}), ('relapsed group CC_entity', {})], 'edges': [('camptothecins_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'}), ('autologous stem cell rescue (ASCR)_entity', 'relapsed group CC_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('novel compounds_entity', {}), ('chemotherapy-resistant disease_entity', {})], 'edges': [('novel compounds_entity', 'chemotherapy-resistant disease_entity', {'type': 'relation', 'relation_type': 'is a treatment for'})]}, {'nodes': [('laparoscopic surgery_entity', {}), ('minimally invasive surgery_entity', {})], 'edges': [('minimally invasive surgery_entity', 'laparoscopic surgery_entity', {'type': 'relation', 'relation_type': 'is_equivalent_to'})]}, {'nodes': [('ExPO-r-Net_entity', {}), ('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', {})], 'edges': [('European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment_entity', 'ExPO-r-Net_entity', {'type': 'relation', 'relation_type': 'related to'})]}, {'nodes': [('University Hospital of Munich_entity', {}), ('Germany_entity', {})], 'edges': [('Germany_entity', 'University Hospital of Munich_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Italy_entity', {}), ('Azienda Ospedaliera, Padova_entity', {})], 'edges': [('Italy_entity', 'Azienda Ospedaliera, Padova_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Prinses Maxima Centrum, Utrecht_entity', {}), ('Netherlands_entity', {})], 'edges': [('Netherlands_entity', 'Prinses Maxima Centrum, Utrecht_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Poland_entity', {}), ('Marciniak Hospital, Wroclaw_entity', {})], 'edges': [('Poland_entity', 'Marciniak Hospital, Wroclaw_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('St. Anna Kinderspital/CCRI, Vienna_entity', {}), ('Austria_entity', {})], 'edges': [('Austria_entity', 'St. Anna Kinderspital/CCRI, Vienna_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('France_entity', {}), ('Armand Trousseau Hospital, Paris_entity', {})], 'edges': [('France_entity', 'Armand Trousseau Hospital, Paris_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Spain_entity', {}), ('Hospital Universitario Virgin del Rocio, Seville_entity', {})], 'edges': [('Spain_entity', 'Hospital Universitario Virgin del Rocio, Seville_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Great Ormond Street Hospital, London_entity', {}), ('UK_entity', {})], 'edges': [('UK_entity', 'Great Ormond Street Hospital, London_entity', {'type': 'relation', 'relation_type': 'location of'})]}, {'nodes': [('Weirich, A._entity', {}), ('SIOP-9/GPOH_entity', {}), ('Children\u2019s Oncology Group study AREN0533_entity', {})], 'edges': [('Weirich, A._entity', 'SIOP-9/GPOH_entity', {'type': 'relation', 'relation_type': 'participated_in'}), ('Weirich, A._entity', 'Children\u2019s Oncology Group study AREN0533_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('Terenziani, M._entity', {}), ('Adult Wilms\u2019 tumor_entity', {})], 'edges': [('Terenziani, M._entity', 'Adult Wilms\u2019 tumor_entity', {'type': 'relation', 'relation_type': 'researched'})]}, {'nodes': [('Daw, N. C._entity', {}), ('vincristine and irinotecan_entity', {}), ('Children\u2019s Oncology Group AREN0321_entity', {})], 'edges': [('Daw, N. C._entity', 'vincristine and irinotecan_entity', {'type': 'relation', 'relation_type': 'studied_treatment'}), ('Daw, N. C._entity', 'Children\u2019s Oncology Group AREN0321_entity', {'type': 'relation', 'relation_type': 'participated_in'})]}, {'nodes': [('high dose therapy in recurrent Wilms\u2019 tumour_entity', {}), ('Ha, T. C._entity', {})], 'edges': [('Ha, T. C._entity', 'high dose therapy in recurrent Wilms\u2019 tumour_entity', {'type': 'relation', 'relation_type': 'proposed_strategy'})]}, {'nodes': [('Kremens, B._entity', {}), ('autologous stem cell rescue_entity', {})], 'edges': [('Kremens, B._entity', 'autologous stem cell rescue_entity', {'type': 'relation', 'relation_type': 'researched_treatment'})]}, {'nodes': [('Furtwangler, R._entity', {}), ('GPOH-nephroblastoma study group_entity', {})], 'edges': [('Furtwangler, R._entity', 'GPOH-nephroblastoma study group_entity', {'type': 'relation', 'relation_type': 'member_of'})]}, {'nodes': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', {}), ('SIOP WT 2001_entity', {})], 'edges': [('SIOP Renal Tumour Study Group (SIOP-RTSG)_entity', 'SIOP WT 2001_entity', {'type': 'relation', 'relation_type': 'developed'})]}, {'nodes': [('National Wilms\u2019 Tumor Study_entity', {}), ('D\u2019Angio, G. J._entity', {})], 'edges': [('D\u2019Angio, G. J._entity', 'National Wilms\u2019 Tumor Study_entity', {'type': 'relation', 'relation_type': 'contributed_to'})]}, {'nodes': [('Prof. Dr Ivo Leuschner_entity', {}), ('SIOP Pathology Panel_entity', {})], 'edges': [('Prof. Dr Ivo Leuschner_entity', 'SIOP Pathology Panel_entity', {'type': 'relation', 'relation_type': 'cochair_and_member_of'})]}]\"])] confident_link=None"